

PUBLIC TRANSLATION INTO ENGLISH-----

Descriptive Memory-----

Of the Invention Patent-----

-

On-----

Recombinant Human Erythropoietin Producing Cell Line and the Recombinant Human Erythropoietin produced by this cell line. -----

Applied for-----

Bio Sidus S. A. -----

For the term of 20 years. -----

There follows the logotype of BIO SIDUS. Constitución 4234 – 1254 Buenos Aires – Argentina. -----

Cell Line producing Recombinant Human Erythropoietin and the Recombinant Human Erythropoietin Produced by this Cell. -----

I. Technical description of the invention-----

The present invention relates to a recombinant human erythropoietin (EPO)-producing cell line, and to the EPO thus produced. Isolation and construction of a gene encoding for EPO, its cloning in proper plasmids to be transfected in mammalian cells. Selection of EPO-producing cell lines, its further culture and production of recombinant EPO. -----

II. Technical field of the invention-----

This invention refers to a recombinant EPO-producing cell line that includes a sequence encoding for EPO with only one promoter that regulates its expression. This invention is also referred to a method to produce EPO.-----

III. Background of the invention-----

EPO is a glycoprotein that stimulates erythroblast differentiation in the bone marrow, thus increasing the circulating blood erythrocyte count. The mean life of

erythrocytes in humans is 120 days and therefore, a human being losses 1/120 erythrocytes each day. This loss must be continuously restored to maintain a stable amount of red blood cells. -----

Existence of EPO was first postulated in the turn of the century and was definitely proved by Reissman and Erslev early in the '50s. See Carnot et al, *C.R. Acad. Sci. (France)*, 143, 384-6 (1906); Carnot et al, *C.R. Acad. Sci. (France)*, 143, 432-5 (1906); Carnot, et al., *C.R. Soc. Biol.*, 111, 344-6 (1906); Carnot, *C.R. Soc. Biol.*, 111, 463-5 (1906); Reissman, *Blood*, 1950, 5, 372-80 (1950) and Erslev, -----

-

AR-98-01-05609 (Este número se repite al pie de cada una de las hojas del cuerpo de la patente, incluyéndose también al pie de cada una de las hojas de las Referencias Adicionales).-----

Blood, 8, 349-57 (1953). Reissman and Erslev's experiments were promptly confirmed by other researchers. See Hodgson et al, *Blood*, 9, 299-309 (1954); Gordon, et al., *Proc. Soc. Exp. Biol. Med.*, 86, 255-8 (1954) and Borsook, et al., *Blood*, 9, 734-42 (1954). -----

Identification of the producing site was an issue of deep debate. Successive experiments led to identify kidney as the main organ and peritubular interstitial cells as the synthesis site. See Jacobson, et al., *Nature*, 179, 633-4 (1957); Kuratowska, et al., *Blood*, 18, 527-34 (1961); Fisher, *Acta Hematol.*, 26, 224-32 (1961); Fisher, et al., *Nature*, 205, 611-2 (1965); Frenkel, et al., *Ann. N.Y. Acad.*

Sci., 149, 1, 292-3 (1968); Busuttil, et al., *Proc. Soc. Exp. Biol. Med.*, 137, 1, 327-30 (1971); Busuttil, *Acta Haematol.*, (Switzerland), 47, 4, 238-42 (1972); Erslev, *Blood*, 44, 1, 77-85 (1974); Kazal, *Ann. Clin. Lab. Sci.*, 5, 2, 98-109 (1975); Sherwood, et al., *Endocrinology*, 99, 2, 504-10 (1976); Fisher, *Ann. Rev. Pharmacol. Toxicol.*, 28, 101-22 (1988); Jelkmann, et al., *Exp. Hematol.*, 11, 7, 581-8 (1983); Kurtz, et al., *Proc. Natl. Acad. Sci.*, (USA.), 80, 13, 4008-11 (1983); Caro, et al., *J. Lab. Clin. Med.*, 103, 6, 922-31 (1984); Caro, et al., *Exp. Hematol.*, 12, 357 (1984); Schuster, et al., *Blood*, 70, 1, 316-8 (1986); Bondurant, et al., *Mol. Cell. Biol.*, 6, 7, 2731-3 (1986); Bondurant, et al., *Mol. Cell. Biol.*, 6, 7, 2731-3 (1986); Schuster, et al., *Blood*, 71, 2, 524-7 (1988); Koury, et al., *Blood*, 71, 2, 524-7 (1988); Lacombe, et al., *J. Clin. Invest.*, 81, 2, 620-3 (1988); Koury, et al., *Blood*, 74, 2, 645-51 (1989). -----

A smaller proportion, ranging from 10% through 15% of total EPO, is produced by the liver in adults. See Naughton, et al., *J. Surg. Oncol.*, 12, 3, 227-42 (1979); Liu, et al., *J. Surg. Oncol.*, 15, 2, 121-32 (1980); Dornfest, et al., *Ann. Clin. Lab. Sci.*, 11, 1, 37-46 (1981); Dinkelaar, et al., *Exp. Hematol.*, 9, 7, 796-803 (1981);

Caro, et al., *Am. J. Physiol.*, 244, 5 (1983); Dornfest, et al., *J. Lab. Clin. Med.*, 102, 2, 274-85 (1983); Naughton, et al., *Ann. Clin. Lab. Sci.*, 13, 5, 432-8 (1983); Jacobs, et al., *Nature*, 313, 6005, 806-10 (1985); Erslev, et al., *Med. Oncol. Tumor. Pharmacother.*, 3, 3-4, 159-64 (1986). EPO is proportionally produced to the degree of tissular hypoxia and its expression rises by increasing the number of producing cells. -----

EPO is a protein that has shown a great efficiency to treat anemia caused of different ethiology, specially anemia secondary to renal failure. Its therapeutical availability, however, was limited till recently due to the lack of a mass production method, since the quantity and quality of EPO obtained by any of the extractive systems knows were not sufficient. Recently, the use of recombinant DNA technology has made it possible to obtain large amounts of proteins. Application of these techniques to eukariotic cells has allowed large scale production of EPO. See patents U.S. 5.688.679 (Powell), 5.547.933 (Lin), 5.756.349 (Lin), 4.703.008 (Lin) and 4.677.195 (Hewick et al.). -----

Recombinant DNA techniques are widely known and currently used. They are based on the manipulation of different genetic elements that facilitate, among other uses, ensamble and transfer genetic constructions and, consequently, allow production of recombinant proteins and the study of biological mechanisms. -----

See Frank-Kamenetskii, "Unraveling DNA" [Samaia Glavnaia Molekula] (Addison Wesley Longman Inc., Reading, Massachusetts, 1997); Brown, "Gene Cloning" (Chapman & Hall, London, England, 1995); Watson, et al., "Recombinant DNA", 2nd Ed. (Scientific American Books, New York, New York, 1992); Aberts et al., "Biología Molecular de la Célula" (Ediciones Omega, 1990); Innis et al., Eds., "PCR Protocols. A Guide to Methods and Applications" (Academic Press Inc., San Diego, California, 1990); Ehrlich, Ed., "PCR Technology. Principles and Applications for DNA Amplification" (Stockton Press, New York, New York, 1989); Sambrook et al., "Molecular Cloning. A Laboratory Manual" (Cold Spring Harbor Laboratory Press, 1989); Bishop et al., "Nucleic Acid and Protein Sequence. A Practical Approach" (IRL Press 1987); Reznikoff, Ed., "Maximizing Gene Expression" (Butterworths Publishers, Stoneham, Massachusetts, 1987); Davis et al., "Basic Methods in Molecular Biology" (Elsevier Science Publishing Co., New York, New York, 1986); Watson, "The Double Helix" (Penguin Books USA Inc., New York, New York, 1969) -----

There follows a rough description of the biological aspects on which recombinant DNA technology is based: -----

DNA (deoxyribonucleic acid) is the genetic material of all living cells and some viruses. Polymeric chains of four different nucleotides form the DNA, each of them being a purine or pyrimidine bound to a desoxyribos, in turn linked to a phosphate group. These four nucleotides are: adenine (A), cytosine (C), guanine (G) and thymine (T). -----

DNA chains are formed by linkages between nucleotides, where the phosphate in position 5' of the deoxyribose of one nucleotide is bound to the 3' position of the deoxyribose of the previous nucleotide. Synthesis *in vivo* occurs from 5' to 3', which is the conventional direction adopted to describe DNA sequences.

Functional DNA is presented as a double helix of complementary bases, where chains are held together by hydrogen bonds formed between A's and C's of one chain and T's and G's of the complementary chain, respectively. This is the reason why they are referred to as "base pairs". -----

The chains are also antiparallel, that is, the 5' end of each helix is matched to the 3' end of the other, as depicted below: -----

5' ---TACGTAC---3'-----


3' ---ATGCATC---5'-----

For protein synthesis to occur certain DNA coding regions are first transcribed to messenger RNA (mRNA). The mRNA is translated in turn into a protein. Each of the DNA coding regions for a protein is called a gene. -----

In the case of nucleated cells, the synthesized RNA may be processed in the nucleus (splicing) to result in mature RNA. This process is verified in bacteria as they have no nucleus. -----

Mature mRNA is then taken as a matrix to be translated into a protein, in a process in which transfer RNA (tRNA, small RNA chains carrying amino acids and specifically aligning them to form the protein) and ribosomes are the main participants. -----

Three mRNA bases (triplet or codon) code each amino acid. For instance, the AUG sequence in mRNA codes for the amino acid methionine. The nucleotides of each mRNA is thus translated into a specific amino acid sequence, called "protein expression". -----



The amount of protein expressed depends, among other factors, on the presence of certain DNA regions called promoters, which affect the rate at which the expression process occurs per time unit.

In addition, there are DNA sequences that indicate the termination of transcription (terminators) and codons which indicate the end of translation (stop codons). -----

During the first years of the 1970 decade, "tools" (restriction enzymes, etc) and other techniques giving rise to recombinant DNA technology were developed.-----

At present, DNA technology involves the isolation of DNA fragments, either natural or synthetic, and their insertion into cells (i.e. bacteria, yeast, insect and mammalian cells) to render them capable of producing heterologous proteins such as EPO. The proteins obtained by this process are called recombinant proteins. -----

The application field of recombinant DNA technology is not limited to cultured cells, since genes can also be incorporated into multicellular organisms (i.e. plants, insects, mammals and fish). -----

The expression of heterologous proteins mainly requires the following elements:

1..A gene coding for the desired protein. The gene may be obtained using different techniques, such as: -----

A Isolation from genomic libraries. -----

-

B *In vitro* synthesis of DNA chains. There are commercially available equipments that synthesize relatively short DNA strands, making it possible to "make up" gene. -----

C.Amplification. Technology that allows to copy several times a DNA fragment of interest, such as a gene. -----

D. Others, i.e. as obtained from mRNA. -----

2.Proper promoters to express a protein in the cell of interest, in the desired amount and moment -----

3. Proper terminators so that transcription is correctly terminated.-----

4.Vectors. Genetic constructions that direct the gene with its promoter and terminator towards the inner region of the cell of interest incorporating the gene either in a chromosome or extrachromosomally. According to the system used, the incorporated gene may remain indefinitely in the cell and be transmitted to its progeny, or be lost in a relatively short term. There are multiple vector systems such as plasmids, and natural or modified viruses. It is also possible to use physical means of DNA introduction such as microinjection. Viruses and plasmids are obtained from nature and are genetically modified *in vitro* to achieve the desired characteristics. -----

5.Others. Additionally, other genetic elements may be necessary to improve the selection of cells receiving the gene (i.e. another gene conferring resistance to antibiotics) or to amplify the number of copies of the gene in each cell (genetic amplification).-----

An ideal expression system, should use vectors and genes being as simple as possible to minimize the risks of obtaining genetically unstable systems or wrong sequences resulting in undesired products. The use of simple vectors and genes reduces the time necessary to develop the system.-----

A fundamental consideration is that genetic simplicity should not disregard the productivity or quality of the protein produced. -----

To achieve the expression of the protein of interest, the appropriate corresponding gene is transfected with the proper vectors within the host cell

genetic material Transfection may be done by different techniques such as electroporation, precipitation with calcium phosphate and the use of lyposomes.-- The gene of interest may be associated to other genes already known to confer resistance, for instance, to antibiotics such as geneticin, or to toxic agents such as methotrexate (MTX). This association allows the selection of the transfected cells in a stable manner, that is, those selected are capable of reproducing and transmitting the gene of interest to their progeny. Association also permits to select the recombinant cells showing the highest expression level.----- The recombinant product thus obtained is identified by analysis of its molecular weight, amino acid sequence, biological activity assays, etc..-----

To present the most widely used genetic engineering techniques to produce EPO are characterized as follow:-----

1.The use of EPO genes including fragments of neighbouring non-coding regions located at 5' and 3' of the same gene. It is conventionally believed that the presence of expression control elements located in siad non-coding regions of the gene is necessary to achieve a high production of EPO. See patent US 5,688,679 . -----

2.The employment of expression vectors with different promoters, based upon the premise that a combination of promoters induces a higher EPO production. Until now, the use of only one promoter included in the vector has resulted in a low level of protein expression. See patents US 4,703,008 (to Lin), US 4,677,195 and US 5,688,679. Average production of EPO using only one promoter is 200 µg//day. Maximum production of EPO reported using only one promoter is 10 mg//day.-----

3. The potential instability of the genetic systems and consequently of EPO production due to the complexity of the genetic constructions utilized.-----

IV. Detailed Description of the Invention-----

The claimed invention consist in an eukariotic cell line that produces recombinant human EPO, obtained by means of transfection with an expression vector that includes a gene that encodes for human EPO, a unique promoter and a terminator as expression control elements. SEQ 1 identifies the EPO amino acid sequence that is codified by the gene used. -----

One of the advantages of this invention is that the EPO encoding gene used does not include fragments of the 5' and 3' neighbouring regions that do not encode for the protein. Despite this, the system claimed produces large amounts of EPO. -----

An additional advantage of this invention is the production of large amounts of

EPO using expression vectors bearing only one promoter. By using the claimed method, it is possible to obtain more than 50 mg of EPO per liter of culture per day, that is, over five-fold the EPO production level claimed by already known methods. -----

-

Combination of the EPO-codifying gene used in this invention and a simple promoter showed, surprisingly, to operate efficiently, obtaining stably transfected cells that produce EPO yields comparable to, or even higher than, the ones reported using in theory more adequate genetic constructions, though more complex and harder to manipulate. -----

A further additional advantage of the claimed invention is cotransfection with two

vectors that confer different resistances, thus making selection, genetic amplification and maintenance of co-transfected producing cells easier.-----

In order to obtain the cell line subject of the claimed invention, genomic DNA extracted from human white blood cells is prepared. The EPO-encoding gene is obtained from conditioned DNA. To achieve this, the gene is amplified using primers that avoid presence of 5' and 3' neighbouring regions of the EPO gene that do not encode for the protein. These primers include in their 5' end region, restriction sites that remain then inserted to both ends of the isolated gene and thus facilitate further cloning. -----

Then, the amplified gene is cloned in a bacterial vector and is sequenced. Once it has been proved that the sequence obtained is correct, the gene is cloned in the Xho I-Hind III sites of an expression vector for eukariotic cells that employs, as expression controller, only the early promoter of SV40 and its terminator. The vector confers resistance to Geneticin and Ampicillin.-----

Then, CHO cells are cotransfected with the expression vector obtained and a second vector that confers resistance to Methotrexate.-----

Stably transfected cells are selected according to their resistance to Geneticin and EPO expression is amplified by selecting cells resistant to increasing amounts of Methotrexate. -----

Finally, clones are selected according to their productivity level as measured by radioimmunoassay. Culture supernatants of the most productive clones are used to test the identity of the EPO produced and its biological activity by SDS-PAGE, Western blot, glycanase treatment followed by SDS-PAGE, isoelectrofocusing, complete protein sequence and in vivo biological activity in ex-hypoxic polycythemic mice challenged versus the international EPO standard.

Processes listed above are performed employing molecular biology techniques that are exemplified below: -----

Example 1 Preparation of Human Genomic DNA.-----

10 ml of blood in 10 mM EDTA (pH 8) were extracted from a clinically healthy adult male subject. The blood was transferred in 5 ml aliquots to two 50 ml tubes, to which 45 ml of a solution containing 0.3 M of saccharose, 10 mM Tris-HCL (pH 7.5), 5 mM Mg Cl₂ and 1% of Triton X 100 was added. The resulting solution was stored at 4° C. -----

The solution was then placed on ice for 10 minutes and centrifuged for 10 minutes at 1000 g and at 4°C. The supernatant was discarded and the pellet was washed up several times with a 0.075 M NaCl solution containing 0.025 M EDTA (pH 8), followed by centrifugation for 10 minutes at 1000 g and at 4°C.-----

The resulting pellet thus obtained was resuspended in 3 ml of a 10mM Tris-HCl (pH 8), 400 mM NaCl, 2 mM EDTA (pH 8) solution. 200 µl of 10 % SDS (sodium dodecyl sulphate) and 500 µl K proteinase (1 mg/ml in 1 % SDS and 2 mM EDTA pH 8) were then added, and the solution was incubated overnight at 37°C. After this incubation, 1 ml of NaCl saturated solution was added; the solution was shaken and then centrifuged at 2500 g for 15 minutes.-----

The supernatant was transferred to a 15 ml tube where the volume was duplicated by the addition of isopropanol. The supernatant and isopropanol were gently mixed by inversion of the tube and stored at room temperature until a DNA precipitate was formed, which was "fished" with a Pasteur blent glass pipette. -----

-
The DNA was placed in a 2 mL tube, and 1 mL of 70 % ethanol was added. After the solution was left stand for one minute, the supernatant was discarded and the precipitate was left to dry. After drying, the precipitate was suspended in 500 µl of TE (10 mM Tris-HCl pH 8 - 1 mM EDTA). -----
Concentration of DNA solution was calculated by measuring the absorbance at

260 nm of a 1:1000 dilution of this solution. Each unit of optical density was considered to have 50 µg of genomic DNA. Once the concentration was known, a solution was prepared with 500 ng of genomic DNA per µl in TE.-----

Example 2 . Isolation of EPO encoding gene -----

-
Gene encoding for EPO was prepared from 500 ng of human genomic DNA obtained in Example 1, adding 400 ng of each of the EPO 1 and EPO 2 primers, in an aqueous 2.5 mM solution containing each deoxynucleotide (dATP, dCTP, dGTP and dTTP), 2.5 units of Taq DNA polymerase (Perkin Elmer) in a final volume of 100 µl using the buffer recommended by the manufacturer. A Perkin Elmer-Cetus Thermal Cycler 480 was used and was programmed for 30 cycles of: 1 minute at 93°C, 1 minute at 55°C and 3 minutes at 72°C. From this reaction, a fragment of approximately 2170 pair bases containing the EPO gene was obtained. -----

Sequence of oligonucleotides employed was: -----

EPO 1: 5' GAATTCTCGAGATGGGGGTGCACGGTGAG 3' (SEQ NO:2),
corresponding to the first bases translated from the EPO gene with the addition of a recognition site for the Xho I enzyme and one for the recognition of Eco RI enzyme to the 5' end. These sites were used in the subsequent cloning steps.---

EPO 2: 5' AAGCTTGGACACACCTGGTCATCTG 3' (SEQ NO:3),
complementary to the last translated bases and to some of the non-encoding 3' of the EPO gene. A site for the recognition of the Hind III enzyme was added to-

the 3' end. This site was used in subsequent cloning steps. -----

The sequence obtained is as follows (SEQ NO:4): -----

gaattctcgagatgggggtgcacggtgagtactcgcggtggcgctcccgccgcccgggtccctgttgag
cggggatttagcggccggctattggccaggaggtggctgggtcaaggaccggcgactgtcaaggaccccg
gaagggggaggggggtggggcagcctccacgtgccagcggggactgggggagtcctggggatggcaaa
aacctgacctgtgaaggggacacagtttgggggtgaggggaagaaggttgggggtctgtgtgccagtga
gaggaagctgataagctgataacctgggcgtggagccaccacttatctgccagaggggaagcctctgtcaca
ccaggattgaagttggccggagaagtggatgctggttagctgggggtgggtgtgcacacggcagcaggattg
aatgaaggccaggaggcagcacctgagtgtgcatggtggggacaggaaggacgagctggggcagag
acgtggggatgaaggaagctgtcctccacagccacccttctccctcccgctgactctcagcctggctatctgtt
ctagaatgtcctgcctggctgtggcttctcctgtccctgtgtcgctccctctgggcctcccagtcctgggcgcccc
ccacgcctcatctgtgacagccgagtcctggagaggtacctctggaggccaaggaggccgagaatatcacg
gtgagaccccttcccagcacattccacagaactcacgctcagggttcagggaactcctccagatccagga
acctggcacttggttgggggtggagttgggaagctagacactgccccctacataagaataagtctggtggcccc
aaaccataacctggaaactaggcaaggagcaaagccagcagatcctacggcctgtgggccagggccagagc
cttcagggacccttgactccccgggtgtgtgcatttcagacgggtgtgtgaacactgcagcttgaatgagaat
atcactgtcccagacaccaaagttaatttctatgcctggaagaggatggaggtgagttcttttttttttctttctt
tgagaatctcatttgcgagcctgatttggatgaaagggagaatgatcggggaaaggtaaaatggagcagc
agagatgaggctgcctgggcgcagaggctcacgtctataatcccaggctgagatggccgagatgggagaatt
gcttgagccctggagtttcagaccaacctaggcagcatagtgagatcccccattctctacaaacatttaaaaaat
tagtcaggatgaagtgggtgcatggtgtagtcccagatatttgaaggctgaggcgggaggatcgctgagccca
ggaatttgaggctgcagtgagctgtgatcacaccactgcactccagcctcagtgacagagtaggccctgtctc
aaaaaagaaaaagaaaaaagaaaaataatgagggtgtatggaatacattcattattcattcactcactcactca
ctcattcattcattcattcattcaacaagtcttattgcataccttctgttgcagcttggtgcttggggctgtgagggg
caggaggagaggggtgacatgggtcagctgactcccagagtccactccctgtaggctgggcagcaggccgta
gaagtctggcagggcctggccctgtgtcggaagctgtcctgcggggccaggccctgttggtcaactctcccag
ccgtgggagcccctgcagctgcatgtggataaagccgtcagtggccttcgcagcctcaccactctgcttggggct

ctgggagcccaggtgagtaggagcggacacttctgcttgcccttctgtaagaaggggagaaggggtcttgctaa
 ggagtacaggaactgtccgtattccttcccttctgtggcactgcagcgacctcctgttttctccttggcagaaggaa
 gccatctcccctccagatgcggcctcagctgctccactccgaacaatcactgctgacactttccgcaaactcttcc
 gagtctactccaatttctccggggaaagctgaagctgtacacaggggaggcctgcaggacagggggacagat
gaccaggtgtgtccaagctt-----

The first translated atg codon, as well as the tga “stop” codon are underlined.
 The sequences of restriction sites utilized in the cloning are shown in bold italics.

Example 3. Cloning and sequencing of the Isolated Gene. -----

A fragment of approximately 2170 base pairs corresponding to the EPO gene was purified and the ends were blunted by treatment with the RNA polymerase Klenow fragment and cloned in the Sma I site of a M13mp18 vector, following standard techniques applied in molecular biology. The recombinant plasmids obtained were cut with the Xho I and Hind III enzymes; the presence of the insert was verified by electrophoresis of the product resulting from the restriction fragments in a 0.8 % agarose gel developed with ethidium bromide stain. A positive clone (two bands, one having approximately 2200 base pairs and the other one corresponding to the linear vector) was chosen and manually sequenced according to the Sanger’s technique using a “T7 sequencing kit” (Pharmacia) and with the aid of an automatic sequences Model 370 A Applied Biosystems International. For each sequencing system the protocols recommended by the manufacturers were followed. -----

Example 4. Vectors for Eukaryotic Cells-----

1. Construction of pVex 1 Vector-----

-

The pVex1 vector was built following the conventional techniques used in molecular biology. It consisted of: -----

- a. Fragments of the bacteria1 pBR322 vector, which conferred a bacterial replication origin and resistance to ampicillin, for amplification and selection of the vector in *E. coli*. -----

b. Immediately close to 3' of a) an early promoter of the SV40 virus is located, which allows the expression of the genes cloned at 5' from this element.-----

c.Immediately close to 3' of b) the Xho I and Hind III cloning sites are located, which allow insertion of the genes to be expressed.-----

d.Immediately close to 3' of c) the polyadenylation signal of the SV40 virus is located, which allows the proper polyadenylation of the specific transcripts of the gene cloned in c). -----

e.Immediately close to 3' of d) the TK promoter and the gene coding for neomycin phosphotransferase plus the polyadenylation signal are located to allow the selection of stably transfected cells through selection by resistance to neomycin and neomycin-derived antibiotics such as genetecin. The 3' end of e) is linked to the 5' end of a). -----

-

A specimen of vector pVex 1 is deposited in the Argentine Cell Bank Association, deposit number ABAC-P-001.-----

B. pDHFR Vector-----

-

The pDHFR vector confers resistance to ampicillin to aid in selection in bacteria. and includes the DNA copy encoding for mice dehydrofolate reductase (DHFR), whose expression is controlled by the SV40 virus early promoter and its polyadenylation signal. -----

The coexpression of DHFR and the EPO-encoding gene allows, through selection by adding methotrexate (MTX) to the culture medium, several times-amplification of EPO expression achieved with the pVex 1-EPO vector.-----

A specimen of the pDHFR vector is deposited in the Argentine Cell Bank Association, deposit number ABAC-P-002. -----

Example 5. Cloning of the EPO-Encoding gene into an Expression Vector--

The sequenced gene was removed by cleavage with the Xho I-Hind III enzymes

of the vector where it was cloned in Example 3. It was then isolated and cloned in the same restriction sites of the pVex I vector. A positive pVex-EPO clone was isolated. All these operations were performed according to the conventional genetic engineering techniques. See Brown, *Gene Cloning* Chapman & Hall, London, England, 1995; Watson, et al., *Recombinant DNA*, 2nd Ed. Scientific American Books, New York, New York, 1992; Sambrook et al, *Molecular Cloning. A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 1989; Bishop et al., *Nucleic Acid and Protein Sequence. A Practical Approach*, IRL Press, 1987; Davis et al., *Basic Methods in Molecular Biology*, Elsevier Science Publishing Co., New York, New York, 1986. -----

Example 6. Co-transfection and amplification with MTX-----

-
A CHO (Chinese Hamster Ovary) cell line, mutated to be deficient in the DHFR-enzyme gene (CHO-DHFR), was used to facilitate the genetic amplification with MTX. -----

During this whole process, cells were grown at 37° C in a 5% of CO₂ atmosphere. -----

CHO cells were cotransfected following the calcium phosphate technique which, for a 90 mm-diameter Petri dish, consists in: -----

(a) Replacing the culture medium (alpha-MEM, with 10 % of bovine fetal serum) with fresh medium 4-8 hours before transfection. -----

(b) Adding to a 5 mL tube a 10 g/l HEPES solution (pH 7.1), 16 g/l NaCl and 10 µl of a 35 mM Na₂HPO₄ and 35 mM of NaH₂PO₄ solution.-----

(c) Preparing in a separate 1.5 ml tube a solution with 60 µl of 2 M CaCl₂ and 10 µg of each DNA to be transfected (pVex-EPO and pDHFR). Water was added until the volume reached 500 µl. The pDHFR plasmid described in Example b is based on the pBR 322 plasmid, which confers resistance to ampicillin, can replicate in *E.coli*, has the DHFR gene cloned between the early promoter and

the terminator of the SV40, and allows the expression of the DHFR protein in CHO cells. This protein confers resistance to methotrexate, which can be then used to select cells having a high erythropoietin productivity.-----

(d) Adding drop by drop, the solution containing DNA and CaCl_2 to the tube containing Hepes, while air is bubbled to obtain a rapid mixing and to make the local concentrations as small as possible. This method facilitates the formation of a very thin precipitate which is more effectively incorporated by the cells.-----

(e) The solution is allowed to settle for 30 minutes and then is poured on the cells. -----

(f) The solution is distributed among the cells through gentle shaking, and left overnight in an incubator at 37°C under a 5% CO_2 atmosphere.-----

(g) The cells are washed twice with PBS (8 g NaCl; 0.2 g KCl; 1.44 g Na_2HPO_4 , 0.24 g NaH_2PO_4 , water is added until the volume reached 1 liter and pH is adjusted to 7.4 with HCl. Fresh culture medium is then added.-----

Twenty four hours after transfection, the selection with genetycin (G 418) at a final concentration of 600 $\mu\text{g/ml}$ was begun. The cells that stably incorporated the pVex-EPO plasmid were able to resist the antibiotic while all the others died after 25 days. Resistant colonies were selected and their productivity was assayed. Once the clones were identified, the three most productive ones were selected. -----

Taking advantage of the genetic constructions used in the invention, a selection was performed with each of the three clones using a second selective agent: MTX at different concentrations: 10^{-8}M , 10^{-7}M , 10^{-6}M , 10^{-5}M . For that purpose, the culture medium was changed to alpha-MEM without nucleosides, supplemented with 10% dialyzed bovine fetal serum. It was essential to perform the dialysis process according to the following schedule: for 100 ml of serum, the serum is placed in a dialysis bag with a porosity under 3000 Da (with a higher porosity, growth factors would be lost, and the cells would not be able to grow

and reproduce), the bag is hermetically closed, and completely immersed in a recipient with 5 liters of bidistilled water; where it is left at 4°C for 12 hours. After this, the water is discarded and again 5 liters are added and the bag is then left stand at 4°C for an additional 12 hour period. Then the dialysis bag is removed and the serum is recovered. Dialysis during shorter periods or with smaller volumes, or without replacing the water, would be worthless since a small amount of nucleotides could be left in serum, and therefore the selection with MTX would not work. Dialysis during longer periods would also be worthless since some proteins, necessary for cell growth, could precipitate and be lost.-----

Example 7. Isolation of high productivity clones-----

Clones that grew in 10^{-7} and 10^{-6} M of MTX were isolated, amplified in fresh alpha-MEM without nucleosides supplemented with 10% of dialyzed bovine fetal serum. Once grown, the culture supernatant was assayed to measure EPO production and secretion. For that purpose, a specific immunoassay was used.-- The process described above concluded with the selection of a clone of recombinant cells producing 50,000 µg of erythropoietin/liter of culture medium per day. -----

A specimen of recombinant cells employed is deposited in the Argentine Cell Bank Association, deposit number ABAC-L-200. -----

Cell transcripts specific for EPO were controlled as described in Example 8, to verify that there were no mistakes in the DNA sequence used or in its transcription. In order to identify the protein obtained, it was proceeded as described in Example 9. -----

Example 8. Verification of the Specific messenger RNA Sequence Produced by the Recombinant Cells-----

A.Preparation of RNA from cells. -----

Total RNA was prepared from producing cell lines, according to the following protocol: -----

a. 90-mm diameter Petri dish with confluent cells was washed twice with 10 ml of PBS. -----

b. Two ml of GTC buffer were then added and spread all over the dish. The GTC buffer was composed of: (1) 50 g guanidinium thiocyanate; (2) 0.5 g N-Lauroilsarcosine; (3) 2.5 ml 1 M sodium citrate, pH 7; (4) 0.7 ml β -mercapthoethanol; (5) 0.33 ml 30% antifoam agent (SIGMA); (6) H₂O q.s.. 100 ml, pH 7.0. -----

Cells were lysed resulting in a highly viscous solution. The solution was transferred to a 15 ml tube, and the process above described was repeated once more using 2 ml of GTC buffer. -----

a) The 15 ml tube was vigorously shaken for 1 minute to break the DNA. Fractioning in a cesium chloride gradient was then performed. For that purpose, 4 ml of a solution containing CsCl (95.97 g CsCl and 2.5 ml of 1 M Sodium Acetate, pH 5.4, water was added to reach a volume of 100 ml) were poured in an ultracentrifuge tube. Over this solution and without mixing, the suspension of the cells in GTC was added. The tube was then filled with GTC buffer and ultracentrifuged at 20°C, for 20 hours at 31000 rpm.-----

b) The RNA remained at the bottom of the tube (pellet) and the DNA formed a band in the middle of the cesium chloride gradient.-----

c) The supernatant was discarded, taking special care to eliminate all of the DNA. The RNA-containing pellet was left to dry for 5 minutes.-----

d) The pellet was dissolved in 200 μ l of water and transferred to a 1.5 ml tube.---

e) 200 μ l of 0.4 M Sodium Acetate, pH 4.8, and 2 volumes of ethanol were then added, the resulting solution was thoroughly mixed and left to stand for 30 minutes at -80°C. -----

f) The solution was then centrifuged in a microcentrifuge at 14000 rpm for 15 minutes, the supernatant was discarded and the precipitate was rinsed with 1 ml of 80 % ethanol. -----

g) The pellet was dried and redissolved in 100 µl of water. -----

f) The concentration of a 1:100 dilution of the RNA solution was measured at 260 nm (one optical density unit is equivalent to 40 µg of RNA). -----

NOTE: All the solutions and elements used were RNAase-free.-----

b. Preparation of specific cDNA-----

Specific cDNA was prepared following the directions of a kit intended for that purpose (cDNA Synthesis System Plus, Amersham - cat. RPN 1256). EPO2 oligonucleotide was used as specific the primer. -----

c. Cloning of cDNA Encoding for EPO-----

1/20th of the obtained cDNA was amplified using 400 ng of each the EPO2 and EPO3 oligonucleotides, and 2.5 mM of each deoxynucleotide in the proper buffer, and 2.5 units of Taq DNA polymerase, in a total volume of 100 µl. -----

Thirty five amplification cycles were performed as follows: 1 minute at 93°C, 1 minute at 55°C and 1 minute at 72°C. -----

EPO 3 was synthesized as described for **EPO 1** and **EPO-2**, and its sequence (5' GAATTCCATGGGGGTGCACGAATGTCC 3') (SEQ ID NO:5) corresponded to the first 20 bases encoding for the EPO cDNA, adding one site for the recognition of the Eco RI enzyme, to facilitate the subsequent genetic manipulations. -----

A fragment of approximately 600 base pairs was obtained, which was cloned in M13mp18 and M13mp19 vectors. -----

The presence of the insert in the clones with restriction fragments was assayed and sequenced in both directions to obtain the complete sequence, using the Sanger's method. -----


Due to the very high autocomplementarity of some regions of the gene, which gives rise to many and very ambiguous compressions in the radioautography, a sequencing kit using Taq DNA polymerase and modified bases was used. Lower

quality results were obtained, but the compressions were eliminated. The kit used was the Pharmacia-LKB Biotechnology *Gene aTaq*.-----
The complete sequence of the human erythropoietin DNA copy, isolated and cloned, showed to encode for EPO. Therefore, no mistakes in the gene or in its transcription were possible. -----

Example 9. Analysis on the EPO Produced -----

The EPO obtained by culturing the cells of this example underwent different quality and identification assays. -----

- a) In a denaturing SDS-PAGE gel the EPO was identified as a wide band of molecular weight superior to 30 kDa. See Figure 1. -----
- b) The band was recognized by a monoclonal antibody and by a polyclonal antibody to human EPO in a "Western blot" assay. See Figure 2.-----
- c) Treatment with glycanases proved the existence of the glycosidic chains whose quantity and molecular weight were as expected. See Figure 3.-----
- d) The EPO produced proved to be composed of a series of species with isoelectric points ranging from 3.0 to 4.5. See Figure 4.-----
- e) The complete amino acid sequence of the isolated protein, purified from the culture supernatant of transfected cell lines showed total homology with natural human erythropoietin whose 165 aminoacid sequence is as follows (SEQ NO:1):



NH₂-----

Ala	Pro	Pro	Arg	Leu	Ile	Cys	Asp	Ser	Arg
Val	Leu	Glu	Arg	Tyr	Leu	Leu	Glu	Ala	Lys
Glu	Ala	Glu	<u>Asn</u>	Ile	Thr	Thr	Gly	Cys	Ala
Glu	Hys	Cys	Ser	Leu	Asn	Glu	<u>Asn</u>	Ile	Thr
Val	Pro	Asp	Thr	Lys	Val	Asn	Phe	Tyr	Ala
Trp	Lys	Arg	Met	Glu	Val	Gly	Gln	Gln	Ala
Val	Glu	Val	Trp	Gln	Gly	Leu	Ala	Leu	Leu
Ser	Glu	Ala	Val	Leu	Arg	Gly	Gln	Ala	Leu
Leu	Val	<u>Asn</u>	Ser	Ser	Gln	Pro	Trp	Glu	Pro
Leu	Gln	Leu	Hys	Val	Asp	Lys	Ala	Val	Ser
Gly	Leu	Arg	Ser	Leu	Thr	Thr	Leu	Leu	Arg
Ala	Leu	Gly	Ala	Gln	Lys	Glu	Ala	Ile	Ser
Pro	Pro	Asp	Ala	Ala	<u>Ser</u>	Ala	Ala	Pro	Leu
Arg	Thr	Ile	Thr	Ala	Asp	Thr	Phe	Arg	Lys

Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala

Sys Arg Thr Gly Asp Arg--- COOH -----

X Glycosilation sites-----

f) The presence of the four glycosilation sites on the 165 amino acid chain, as well as the complex carbohydrate structure, specifically, the sialic acid terminal residues, were demonstrated, as well as its correct *in vivo* biological activity, when assayed by the model of the ex-hypoxic polycythemic mouse assay, which showed a total parallelism versus the corresponding international standard.-----

g) Productivity achieved, measured by a specific immunoassay, was 50 mg per liter of culture per day. -----

V. Description of Diagrams-----


Figure 1 illustrates polyacrilamide gel (SDS-PAGE) analysis of an EPO sample obtained following the method described. In lanes 1, 4 and 7, molecular weight markers were loaded. In lanes 2, 3, 5 and 6, different masses of pure EPO obtained according to the claimed procedure were run. The purity of the product obtained and the apparent molecular weight slightly exceeding 30 kDa - coincident with the one reported for urinary human EPO, can be clearly observed. Figure 2 illustrates a Western blot analysis of an EPO sample obtained according to the method described. Identity of the EPO produced is assessed, since it is recognized by an antibody to human EPO. In lane 1, a human EPO standard was loaded, in lane 2, molecular weight markers and in lanes 3 through 5, EPO samples obtained according to the claimed method.-----

-

Figure 3 shows a SDS-PAGE analysis of a pure EPO sample obtained according to the method described, treated with glycanases. Molecular weight markers were loaded in lanes 1, 4 and 8. Lanes 2 and 7 correspond to untreated EPO. In lane 3, O-glycanase treated EPO was loaded; the presence of an O-

glycosilation is verified. In lane 5, N-glycanase partially degraded EPO was loaded. The presence of 3 N-glycosilations with the molecular weights expected for EPO can be verified. Lane 6 was loaded with EPO degraded with O-glycanase and N.glycanase, and the expected molecular weight for the folly deglycosilated protein was obtained. -----

Figure 4 illustrates a survey of the isoelelctric points in pure EPO samples produced according to the method described. EPO samples were run in lanse 2, 3 and 4, isoelectric point markers in lanes 1 and 5. The presence of forms corresponding to EPO are verified, in an isoelectric point range of 3.0 to 4.5.



VI. What Is Claimed Is: -----

Having described and exemplified the nature and main subject of this invention, as well as the manner in which it can be operated, it is hereby stated to claim as of exclusive property and rights:-----

1. A CELL LINE PRODUCING RECOMBINANT HUMAN ERYTHROPOIETIN characterized by the following: a) the EPO encoding gene is the one detailed in SEQ 4 and consists only in the human EPO gene encoding region, without including 5' and 3'neighbouring regions of the EPO gene that do not encode for the protein, b) the genetic constructs used have, as control elements of EPO expression, a unique viral promoter and terminator, c) the method to construct the EPO encoding gene uses human DNA as source material. -----

2. A CELL LINE THAT PRODUCES RECOMBINANT HUMAN ERYTHROPOIETIN according to claim 1, characterized because the expression genetic systems consist in two vectors that have as control elements of the EPO expression only the early promoter of the SV40 virus and its terminator. -----


3. A CELL LINE THAT PRODUCES RECOMBINANT HUMAN ERYTHROPOIETIN according to claim 1, characterized because the genetic expression systems consist in two vectors that have as a control element for EPO expression the early promoter of the SV40 virus.-----

4. A CELL LINE THAT PRODUCES RECOMBINANT HUMAN ERYTHROPOIETIN according to claim 1, characterized because it comprises a pDHFR vector. -----

5. A CELL LINE THAT PRODUCES RECOMBINANT HUMAN ERYTHROPOIETIN according to claim 1, characterized because cell lines are selected using a double system, 1) resistance to geneticin and 2) resistant to increasing quantities of Methotrexate.-----

A CELL LINE THAT PRODUCES RECOMBINANT HUMAN ERYTHROPOIETIN according to claim 1, characterized because the EPO thus obtained consists in

165 amino acids according to the following sequence: -----



NH ₂ ---	Ala	Pro	Pro	Arg	Leu	Ile	Cys	Asp
	Ser	Arg	Val	Leu	Glu	Arg	Tyr	Leu
	Leu	Glu	Ala	Lys	Glu	Ala	Glu	<u>Asn</u>
	Ile	Thr	Thr	Gly	Cys	Ala	Glu	Hys
	Cys	Ser	Leu	Asn	Glu	<u>Asn</u>	Ile	Thr
	Val	Pro	Asp	Thr	Lys	Val	Asn	Phe
	Tyr	Ala	Trp	Lys	Arg	Met	Glu	Val
	Gly	Gln	Gln	Ala	Val	Glu	Val	Trp
	Gln	Gly	Leu	Ala	Leu	Leu	Ser	Glu
	Ala	Val	Leu	Arg	Gly	Gln	Ala	Leu
	Leu	Val	<u>Asn</u>	Ser	Ser	Gln	Pro	Trp
	Glu	Pro	Leu	Gln	Leu	Hys	Val	Asp
	Lys	Ala	Val	Ser	Gly	Leu	Arg	Ser
	Leu	Thr	Thr	Leu	Leu	Arg	Ala	Leu
	Gly	Ala	Gln	Lys	Glu	Ala	Ile	Ser
	Pro	Pro	Asp	Ala	Ala	<u>Ser</u>	Ala	Ala
	Pro	Leu	Arg	Thr	Ile	Thr	Ala	Asp
	Thr	Phe	Arg	Lys	Leu	Phe	Arg	Val
	Tyr	Ser	Asn	Phe	Leu	Arg	Gly	Lys
	Leu	Lys	Leu	Tyr	Thr	Gly	Glu	Ala
	Cys	Arg	Thr	Gly	Asp	----	COOH	-----

X Glycosilation sites -----

7. A CELL LINE THAT PRODUCES RECOMBINANT HUMAN ERYTHROPOIETIN according to claim 1, characterized because it surprisingly produces large amounts of EPO, higher than 50 mg/liter of culture medium/day.

8. A CELL LINE THAT PRODUCES RECOMBINANT HUMAN ERYTHROPOIETIN according to claim 1, characterized because cells are mammalian cells.

9. A CELL LINE THAT PRODUCES RECOMBINANT HUMAN ERYTHROPOIETIN according to claim 1, characterized because cells are CHO, COS, BHK, Namalwa, HeLa, Hep3B, Hep-G2 or other mammalian cells.

10. A CELL LINE THAT PRODUCES RECOMBINANT HUMAN ERYTHROPOIETIN according to claim 1, characterized because the cells are

CHO or COS. -----
11. A CELL LINE THAT PRODUCES RECOMBINANT HUMAN
ERYTHROPOIETIN according to claim 1, characterized because the cells are
CHO cells. -----

12. A CELL LINE THAT PRODUCES RECOMBINANT HUMAN
ERYTHROPOIETIN according to claim 1, characterized because the genomic
DNA used is obtained from human white blood cells.-----

There follows an illegible signature followed by a seal that reads: HUMBERTO
M. DE PASQUALE. ATTORNEY.-----

VII Diagrams-----

Fig. 1. Polyacrilamide gel electrophoresis analysis (SDS-PAGE) -----




Fig. 2. Western blot analysis -----




Fig. 3. SDS-PAGE analysis of EPO digestion with glycanases -----





Fig. 4. Determination of Isoelectric Point (Isoelectric focusing)-----



VIII. Deposit of Microorganisms -----

The pDHFR vector was deposited on February 2, 1999 in the Argentine Cell Bank Association (ASOCIACIÓN BANCO ARGENTINO DE CÉLULAS – ABAC) under access code ABAC-P002. -----

The pVex 1 vector was deposited on February 2, 1999 in the Argentine Cell Bank Association (ASOCIACIÓN BANCO ARGENTINO DE CÉLULAS – ABAC) under access code ABAC-P001. -----

The claimed recombinant cell line was deposited on February 2, 1999 in the Argentine Cell Bank Association (ASOCIACIÓN BANCO ARGENTINO DE CÉLULAS – ABAC) under access code ABAC-L-200.

IX. Abstract -----

The gene encoding for human erythropoietin (EPO) was obtained from human genomic DNA. The gene used does not include fragments from neighboring regions to the 5' and 3' of the EPO gene that do not encode for the protein. The gene was cloned in an expression plasmid for eukaryotic cells that has as unique expression control elements the early promoter of the SV40 virus and its polyadenilation signal. Recombinant cells resulting from transfection with the genetic constructs used, provide an unexpectedly high level of expression, i.e. 50 mg of recombinant EPO per liter of culture medium per day. -----

X. Additional References -----

Adamson, "Epoetin Alfa: Into the New Millenium", Semin. Onc., 3 (7): 76-79 (June 25, 1998) -----

Alt et al., "Selective Multiplication of Dihydrofolate Reductase Genes in Methotrexate-resistant Variants of Cultured Murine Cells", J. Biol. Chem., 253: 1357-1370 (1978) -----

Anderson et al., "Erythropoietin for the Treatment of Porphyria Cutanea Tarda in a Patient on Long-Term Hemodialysis" N. England J. of Med., 322 (5): 315-317 (1990) -----

Annable et al., "The Second International Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay", Bull Wld. Hlth. Org., 47: 99-112 (1972) -----

Baciu et al., "Erythropoietin Interaction with the Mature Red Cell Membrane", Ann. N.Y. Acad. Sci., 414, 66-72 (1983)-----

Banerji et al., "Expression of a β -Globin Gene is Enhanced by Remote SV40 DNA Sequences Cell", (part i) 27: 299-308 (1981)-----

Barthomeuf et al., "L'EPO Recombinante", Biofutur, 155: 16 (1996)-----

Battersby et al., "Isoforms of Recombinant Human Erythropoietin", Pathophysiology and Pharmacology of Erythropoietin. Springer-Verlag (1992) ----

Begin, "Prediction Response to Treatment with Recombinant Human Erythropoietin in Anaemia Associated with Cancer", Med. Oncol., 15 (Suppl. 1): 38-46 (1998) -----

Benoist et al., "In Vivo Sequence Requirements of the SV40 Early Promoter Region", Nature, 290: 304-310 (1981)-----

Benton et al., "Screening λ .gt Recombinant Clones by Hybridization to Single Plaques in Situ", Science, 196, 180-182 (Apr. 8, 1977) -----

Benz et al., "Hemoglobin Switching in Sheep", J. Biol. Chem., 5025-5032 (1978)

Berk et al., "Sizing and Mapping of Early Adenovirus mRNAs by Gel Electrophoresis of S1 Endonuclease-Digested Hybrids", Cell, 12: 721-732 (1977)

Billat et al., "In Vitro and In Vivo Regulation of Hepatic Erythropoiesis by Erythropoietin and Glucocorticoids in the Rat Fetus", Exp. Hematol., 10 (1), 133-140 (1982) -----

Bos et al., "Eukaryotic Expression of Cloned cDNA Coding for Influenza Viral Glycoproteins Using an SV40 Vector: Use of Recombinant DNA Mutants to Study Structure-Function Relationships.sup.1" Proc. Symp. Mol. Biol. Negat., Strand Viruses Meeting, pp. 125-130, Compans et al., Eds., Academic Press, San Diego, California (1984) -----

Bostock et al., "Gene Amplification in Methotrexate-resistant Mouse Cells", Mol. Biol., 153: 219-236 (1981)-----

Brandan, et al., "In Vitro Assay of Erythropoietin in Fetal Mouse Liver Cultures. 1. Comparison of Radioactive Tracers and Evidence of Assay Specificity", British J. Hematol., 47: 461-468 (1981)-----

Bray et al., "Human cDNA Clones for Four Species of G.alpha.-signal Transduction Protein", P.N.A.S. (USA), 83, 8893-8897 (Dec. 1986) -----

Breslow et al., "Isolation and Characterization of cDNA Clones for Human Apolipoprotein A-I", P.N.A.S. (USA), 79, 6861-6865 (Nov. 1982) -----

Brown et al., "Relationship of Amplified Dihydrofolate Reductase Genes to Double Minute Chromosomes in Unstably Resistant Mouse Fibroblast Cell Lines", Mol. Cell. Biol., 1 (12): 1077-1083 (1981) -----

Browne et al., "Erythropoietin: Gene Cloning, Protein Structure, and Biological Properties", Cold Spring Harbor Symposia on Quantitative Biology, L1, 693-702 (1986)-----

Camiscoli et al., "Comparative Assay of Erythropoietin Standards", Ann. N.Y. Acad. Sci., 149: 40-45 (1968)-----

Canaani et al., "Regulated Expression of Human Interferon .beta.1 Gene after Transduction into Cultured Mouse and Rabbit Cells", P.N.A.S. (USA), 79, 5166-5170 (Sep. 1982)-----

Canadian Erythropoietin Study Group, "Association between Recombinant Human Erythropoietin and Quality of Life and Exercise Capacity of Patients Receiving Haemodialysis", BMJ, 300 (3): 573-578 (1990) -----

Casadevall, "Treatment of Anaemia with RHuEPO in Patients with MDS", Med. Oncol., 15 (Suppl. 1): 35-47 (1998)-----

Cazzola, "How and When to Use Erithropoietin", Curr. Op. Hetmatol., 5 (2): 103-108 (Mar. 1998)-----

Chan et al., "Construction and Selection of Recombinant Plasmids Containing

Full-length Complementary DNAs Corresponding to Rat Insulins I and II", P.N.A.S. (USA), 76(10), 5036-5040 (Oct. 1979)-----

Chernajovsky et al., "Efficient Constitutive Production of Human Fibroblast Interferon by Hamster Cells Transformed with the IFN Gene Fused to an SV40 Early Promoter", DNA, 3: 297-308 (1982)-----

Chapman et al., "Amplification and Hormone-regulated Expression of a Mouse Mammary Tumor Virus-Eco gpt Fusion Plasmid in Mouse 3T6 Cells", Mol. Cell. Biol., 3: 1421-1429 (1983)-----

Chasin et al., "Mutant Alleles for Hypoxanthine Phosphoribosyltransferase: Codominant Expression, Complementation and Segregation in Hybrid Chinese Hamster Cells", Somatic Cell Genetics, 453-467 (1976) -----

Chen et al., "The Primary Structure and Genetic Organization of the Bovine Papillomavirus Type 1 Genome", Nature, 299: 529-534 (1982) -----

Chiba et al., "Stabilization of Urinary Erythropoietin", Biochem. Biophys. Res. Commun., 47(6), 1372-1377 (1972) -----

Choo et al., "Molecular Cloning of the Gene for Human Anti-haemophilic Factor IX", Nature, 299, 178-180 (Sep. 9, 1982)-----

Choppin et al., "Characterization of Erythropoietin Produced by IW32 Murine Erythroleukemia Cells", Blood, 64(2), 341-347 (Aug. 1984)-----

Christman et al., "Amplification of Expression of Hepatitis B Surface Antigen in 3T3 Cells Cotransfected with a Dominant-acting Gene and Cloned Viral DNA", P.N.A.S. 79, 1815-1819 (Mar. 1982)-----

Claus-Walker et al., "Spinal Cord Injury and Serum Erythropoietin", Arch. Phys. Med. Rehabil., 65, 370-374 (Jul. 1984)-----

Colby et al., "Immunological Differentiation Between E. Coli and CHO Cell-Derived Recombinant and Natural Human .beta.-Interferons.sup.1", J. Immunol., 133(6), 3091-3095 (1984)-----

Collen et al., "Biological Properties of Human Tissue-Type Plasminogen

Activator Obtained by Expression of Recombinant DNA in Mammalian Cells", J. of Pharmacology and Exp. Therapeutics, 231(1), 146-152 (1984) -----

Colman, "Cells That Secrete Foreign Proteins", TIBS, 435-437 (Dec. 1982) -----

Congote et al., "Isolation of Two Biologically Active Peptides, Erythropoietin I and Erythropoietin II from Fetal Calf Intestine", Biochem. Biophys. Res. Comm., 115(2), 477-483 (Sep. 15, 1983) -----

Congote et al., "The Erythropoietins, New Erythroid Cell Stimulating Factors Extracted From Human and Bovine Fetal Tissues", Abstract 364, Proceedings 7th International Congress of Endocrinology, (Quebec City, Quebec, Jul. 1-7, 1984)-----

Congote, "High Performance Liquid Chromatographic Separation of Serum Erythropoietin and Erythropoietin", Chromatography, 310: 396-400 (1984) -----

Contrera et al., "Extraction of Erythropoietin from Kidneys of Hypoxic and Phenylhydrazine-treated Rats", Blood, 25(5), 809-816 (May 1965)-----

Corces et al., "Integration, Transcription and Control of a Drosophila Heat Shock Gene in Mouse Cells", Proc. Natl. Acad. Sci. (USA), 78(11): 7038-7042 (1981) --

Corden et al., "Promoter Sequences of Eukaryotic Protein-coding Genes", Science, 209: 1406-1414 (1980) -----

Costantini et al., "Gene Transfer into the Mouse Germ-Line", J. Cell Physiol. Supp. 1, 219-226 (1982)-----

Cotes et al., "Changes in Serum Immunoreactive Erythropoietin during the Menstrual Cycle and Normal Pregnancy", Brit. J. Obstet. Gynaecol., 90, 304-311 (Apr. 1983)-----

Cotes et al., "Bio-Assay of Erythropoietin in Mice Made Polycythaemic by Exposure to Air at a Reduced Pressure", Nature, 191, 1065-1067 (Sep. 9, 1961)

Cotes, "Erythropoietin" Chapter: "Physiological Studies of Erythropoietin in Plasma", Jelkman and Gross Eds., 57-79 (1990)-----

-

Crouse et al., "Expression and Amplification of Engineered Mouse Dihydrofolate Reductase Minigenes", *Mol. Cell. Biol.*, 3:257-266 (1983)-----

Craig Crowley et al., "Plasmid-directed Synthesis of Hepatitis B Surface Antigen in Monkey Cells", *Mol. Cell. Biol.*, 3: 44-55 (1983)-----

Dainiak et al., "Mechanisms of Abnormal Erythropoiesis in Malignancy", *Cancer*, 51(6), 1101-1106 (1983) -----

Danko et al., "Epoetin Alfa for Treatment of Postpartum Anaemia", *The Lancet*, 334: 737-738 (1990) -----

Das et al., "Use of Synthetic Oligonucleotide Probes Complementary to Genes for Human HLA-DR.alpha. and .beta. as Extension Primers for the Isolation of 5'-specific Genomic Clones", *P.N.A.S. (USA)* 80, 1531-1535 (Mar. 1983) -----

-

Davis et al. "A Manual for Genetic Engineering, Advanced Bacterial Genetics", Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 55-58, 174-176 (1983) -----

Davis et al., "Active Influenza Virus Neuraminidase is Expressed in Monkey Cells from cDNA Cloned in Simian Virus 40 Vectors", *Proc. Natl. Acad. Sci. (USA)*, 80, 3976-3980 (1983)-----

Davis et al., "Characterization of Recombinant Human Erythropoietin Produced in Chinese Hamster Ovary Cells", *Biochem* 26: 2633-2638 (1987) -----

De Saint Vincent et al., "The Cloning and Reintroduction into Animal Cells of a Functional CAD Gene, a Dominant Amplifiable Genetic Marker ", *Cell*, 27: 267-277 (1981)-----

DeGowin et al., "The Mouse with Hypoxia-induced Erythremie, an Erythropoietin Bioassay Animal", *J. Lab. Clin. Med.* 60 (5): 846-852 (1962) -----

Derynck et al., "Human Transforming Growth Factor-.alpha.: Precursor Structure and Expression in E. Coli", *Cell*, 38, 287-297 (Aug. 1984)-----

Dessypris et al., "Effect of Pure Erythropoietin on DNA-synthesis by Human Marrow Day 15 Erythroid Burst Forming Units in Short-term Liquid Culture", *Brit.*

J. Haematol., 56, 295-306 (1984) -----

Devos et al., "Purification of Recombinant Glycosylated Human Gamma Interferon Expressed in Transformed Chinese Hamster Ovary Cells", Interferon Research, 4, 461-468 (1984)-----

DiMaio et al., "Bovine Papillomavirus Vector that Propagates as a Plasmid in Both Mouse and Bacterial Cells", Proc. Natl. Acad. Sci., 79: 4030-4034 (1982) ----

DiMaio et al., "High-level Expression of a Cloned HLA Heavy Chain Gene Introduced Into Mouse Cells on a Bovine Papillomavirus Vector", Mol. Cell. Biol., 4: 340-350 (1984) -----

Dolnick et al., "Correlation of Dihydrofolate Reductase Elevation with Gene Amplification in a Homogeneously Staining Chromosomal Region in L5178Y Cells", J. Cell Biol., 83: 394-402 (1979)-----

Dordal et al., "Function and Composition of the Carbohydrate Portion of Human Urinary Erythropoietin", Experimental Hematology, 10, Supp. 11, p. 133, Abstract No. 222 (1982) -----

Dordal et al., "The Role of Carbohydrate in Erythropoietin Action", Endocrinology, 116(6), 2293-2299 (1985)-----

Draganac et al. "Rapid Preparation of Human Urinary Erythropoietin by High Performance Liquid Chromatography", Exptal. Hematol., 11(supl. 14): 58 (1983) -

Dubé et al., "Glycosilation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function", J. of Biol. Chem., 263 (33): 17516-16521 (1988)-----

Dubois et al., "The Development of Indications for the Preoperative Use Of Recombinant Erythropoietin", Canc. J. Surg., 41 (5): 351-365 (1998) -----

Dukes et al., "Erythropoietin: a Complex with Different In Vivo and In Vitro Activities", J. Lab. & Clin. Med. 76(3): 439-444 (1970)-----

Dunn et al., "Use of a Computer Model in the Understanding of Erythropoietic Control Mechanisms", Chemical Abstracts, 91, 190417r (1979) -----

Dunn et al., "Current Concepts in Erythropoiesis", John Wiley & Sons, Chichester, England, (1983) -----

Dunn et al., "Serum Erythropoietin Titers during Prolonged Bedrest; Relevance to the Anaemia of Space Flight", Eur. J. Appln. Physiol., 52, 178-182 (1984) -----

-

Dunn et al., "Erythropoietin Bioassays Using Fetal Mouse Liver Cells: Validations and Technical Improvements", Exp. Hematol., 11(7), 590-600 (Aug. 1983) -----

Edman et al., "A Protein Sequentator", Eur. J. Biochem. 1, 80-91 (1967) -----

Elder et al., "Simian Virus 40 as an Eukaryotic Cloning Vehicle", Ann. Rev. Genet., 15: 295-340 (1981) -----

Edmunds et al., "Blood Pressure and Erythropoietin", The Lancet, 351-2 (February 13, 1988) -----

Emmanouel et al., "Metabolism of Pure Human Erythropoietin in the Rat", Am. J. Physiol., 247 (1 Pt 2), F168-76 (1984)-----

Ersley, "Erythropoietin Coming of Age", N. England J. of Med. 316 (2): 101-103 (1987) -----

Eschbach et al., "Correction by Erythropoietin (EPO) Therapy of the Anemia of Chronic Renal Failure (CRF) in Sheep", Clin. Res. 29(2), 518A (1981) -----

Eschbach et al., "The Anemia of Chronic Renal Failure in Sheep", J. Clin. Invest., 74(2), 434-441 (Aug. 1984)-----

Eschbach et al., "Correction of the Anemia of End-stage Renal Disease with Recombinant Human Erythropoietin", N. England J. of Med. 316 (2):73-78 (1987)-----

Eschbach et al., "Recombinant Human Erythropoietin: Implications for Nephrology", Am. J. of Kidney Diseases XI (3): 203-209 (1988)-----

Eschbach, "The Anemia of Chronic Renal Failure: Pathophysiology and the Effects of Recombinant Erythropoietin", Kidney Int., 35: 134-148 (1989) -----

-

Espada et al., "A New Method for Concentration of Erythropoietin from Human

Urine", *Biochemical Medicine*, 3: 475-484 (1970)-----

Espada et al., "Purificación de Eritropoyetina Urinaria Humana", *Acta Physiol. Latinoamer.*, 20: 122-129 (1970)-----

Espada et al., "Purification of Human Urinary Erythropoietin", *Fed. Proc.*, 41, 1159 (1982) -----

Farber et al., "Translation of mRNA from Human Kidneys into Biologically Active Erythropoietin Following Microinjection into *Xenopus Laevis* Oocytes", *J. Lab. Clin. Med.*, 102, 681 abstract (Nov. 1983)-----

Farber et al., "Translation of mRNA from Anemic Baboon Kidney into Biologically Active Erythropoietin", *Exp. Hematol.*, 11, Supp. 14, Abstract 101 (1983) -----

Farber, "Translation of RNA from Human Kidneys into Biologically Active Erythropoietin Following Microinjection into *Xenopus Laevis* Oocytes", *Clin. Res.*, 31(4), 769A (Nov. 1983)-----

Farber et al., "Translation of mRNA from Human Kidneys into Biologically Active Erythropoietin Following Microinjection into *Xenopus Laevis* Oocytes", *Blood*, 62(5), Supp. No. 1, Abstract 392, 122a (1983)-----

Fauld et al., "Epoetin (Recombinant Human Erythropoietin)", *Drugs*, 38 (6): 864-899 (1989) -----

Fiers et al., "The Human Fibroblast and Human Immune Interferon Genes and Their Expression in Homologous and Heterologous Cells", *Phil. Trans. R. Soc. Lond.*, B299, 29-38 (1982)-----

Finch, "Erythropoiesis, Erythropoietin, and Iron", *Blood*, 60(6), 1241-1246 (Dec. 1982) -----

Firkin, "Recombinant Human Erythropoietin Enters the Pharmacopeia", *Aust. N.Z. J. Med.* 19: 279-280 (1989)-----

Fisher et al., "Cooperative Erythropoietic Assay of Several Steroid Metabolites in Polycythemic Mice", *Steroids*, 30(6), 833-845 (Dec. 1977) -----

Fisher, "Erythropoietin: Pharmacology, Biogenesis and Control of Production",

Pharmacological Review, 24(3), 459-508 (1972)-----

Fisher, "Control of Erythropoietin Production", Proc. Soc. Exp. Biol. & Med., 173, 289-305 (1983) -----

Fisher et al., "Effects of Testosterone, Cobalt & Hypoxia on Erythropoietin Production in the Isolated Perfused Dog Kidney", Ann. N.Y. Acad. Sci., 75-87 (1967) -----

Flaharty et al., "Epoetin: Human Recombinant Erythropoietin", Clin. Phar., 8: 769-782 (1989) -----

Flaharty et al., "Pharmacokinetics and Erythropoietic Response to Human Recombinant Erythropoietin in Healthy Men", Clin. Pharmacol. Ther., 47 (5): 557-564 (1990) -----

Food and Drug Administration, Department of Health and Human Services, Office of Biologics Research and Review Center for Drugs and Biologics, "Points to Consider in the Production and Testing of New Drugs and Biologicals produced by Recombinant DNA Technology (April 10, 1985) -----

Fukuda et al., "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates", Blood, 73 (1) 84-89 (1989)-----

Garcia et al., "Radioimmunoassay of Erythropoietin: Circulating Levels in Normal and Polycythemic Human Beings", J. Lab. Clin. Med., 99, 624-635 (May 1982) ---

Garcia et al., "Radioimmunoassay of Erythropoietin", Blood Cells, 5, 405-419 (1979) -----

Garcia et al., "Immunological Neutralization of Various Erythropoietins", Proc. Soc. Exptl. Biol. Med., 112, 712-714 (1963) -----

Garcia, "The Radioimmunoassay of Human Plasma Erythropoietin", First International Conference on Hematopoiesis, Regulation of Erythropoiesis (Milan) 1972, 132-155-----

Gasser et al., "Expression of Abbreviated Mouse Dihydrofolate Reductase Genes in Cultured Hamster Cells", P.N.A.S. (USA), 79, 6522-6526 (Nov. 1982) --

Gene Screen, New England Nuclear, Catalog No. NEF-972. -----

Gething et al., "Comparison of Different Eukaryotic Vectors for the Expression of Hemagglutinin Glycoprotein of Influenza Virus", Modern Approaches To Vaccines, pp. 263-268, Chanock et al., Eds. Cold Spring Harbor Lab (1984) -----

Gething et al., "Cell Surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene", Nature, 293: 620-625 (1981) -----

Gething et al., "Construction of Influenza Haemagglutinin Genes that Code for Intracellular and Secreted Forms of the Protein", Nature, 300:598-603 (Dec. 16, 1982) -----

Ghosh et al., "Identification of a Promoter Component Involved in Positioning the 5'termini of Simian Virus 40 Early mRNAs", Proc. Natl. Acad. Sci., 78: 100-104 (1981) -----

Gibson et al., "An Evaluation of Serum Erythropoietin Estimation By a Hemagglutination Inhibition Assay in the Differential Diagnosis of Polycythemia", Pathology, 16, 155-156 (Apr. 1984) -----

Gluzman, "SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants", Cell, 23, 175-182 (Jan. 1981) -----

Goeddel et al., "Synthesis of Human Fibroblast Interferon by E. Coli", Nucleic Acids Res., 8 (18), 4057-4074 (1980) -----

Goeddel et al., "Human Leukocyte Interferon Produced by E. Coli is Biologically Active", Nature, 287:411-416 (Oct. 2, 1980) -----

Goldberg et al., "Regulation of the Erythropoietin Gene: Evidence that the Oxygen Sensor is a Heme Protein", Science, 242: 1412-1415 (1988) -----

Goldberg et al., "The Regulated Expression of Erythropoietin by Two Human Hepatoma Cell Lines", Proc. Natl. Acad. Sci. (USA), 84: 7972-7976 (1987) -----

Goldwasser et al., "Erythropoietin: Assay and Study of Its Mode of Action", Meth. in Enzymol., 37, 109-121 (1975) -----

Goldwasser, "From Protein to Gene to Protein: The Molecular Biology of Erythropoietin", Am. J. of Kidney Diseases, 18(4) Supp. 1, 10-13 (Oct. 1991) -----

Goldwasser, "Biochemical Control of Erythroid Development", Current Topics in Developmental Biology, A. Monroy and A.A. Noscona, Eds., 173-211, Academic Press, New York, New York (1966) -----

Goldwasser et al., "The Molecular Weight of Sheep Plasma Erythropoietin", J. of Biol. Chem., 247(16), 5159-60 (Aug. 25, 1972) -----

Goldwasser et al., "Progress in the Purification of Erythropoietin", Ann. N.Y. Acad. Sci., 149:49-53 (1968) -----

-

Goldwasser et al., "Part II. Chemistry and Purification of Erythropoietin", Ann. N.Y. Acad. Sci., 149: 49-53 (1968)-----

Goldwasser et al., "On the Mechanism of Erythropoietin-induced Differentiation", J. of Biol. Chem., 249(13), 4202-4206 (Jul. 10, 1974) -----

Goldwasser et al., "Purification of Erythropoietin", P.N.A.S. (USA), 68(4), 697-698 (Apr. 1971) -----

Goldwasser et al., "On the Purification of Sheep Plasma Erythropoietin", Erythropoiesis, 43-49 (1962)-----

Goldwasser et al., "Further Purification of Sheep Plasma Erythropoietin", Bioch. Biophys. Acta, 64, 487-496 (1962) -----

Goldwasser, "Some Thoughts on the Nature of Erythropoietin-Responsive Cells", J. Cell Physiol., 110 (Supp. 1), 133-135 (1982) -----

Goldwasser et al., "An Assay for Erythropoietin In Vitro at the Milliunit Level", Endocrinology, 97(2), 315-323 (Aug. 1975) -----

Goldwasser et al., "Erythropoietin and the Differentiation of Red Blood Cells", Fed. Proc. 34, 2285-2292 (Dec. 1975) -----

Goochee et al., "Enviromental Effects on Protein Glycosylation", Biotechnology, 8, 421-427 (May 1990) -----

Goochee et al., "The Oligosaccharides of Glycoproteins: Bioprocess Factors

Affecting Oligosaccharide Structure and their Effect on Glycoprotein Properties",
 Biotechnology, 9, 1347-1555 (Dec. 1991) -----

Goodman et al., "Cloning of Homone Genes from a Mixture of cDNA Molecules",
 Meth. in Enzymol., 68, 75-90 (1979) -----

Goodnough et al., "Increased Preoperative Collection of Autologous Blood with
 Recombinant Human Erythropoietin Therapy", N. England J. of Med., 321 (17)
 (1989) -----

Goodnough, "The Use of Erythropoietin in the Enhancement of Autologous
 Tranfusion Therapy", Curr. Opin. Hematol., 2 (3): 214-218 (1995) -----

Goeddel, "Human Leukocyte Interferon Produced by E. Coli is Biologically
 Active", Nature, 287: 411-416 (1980)-----

Gordon et al., "A Plasma Extract with Erythropoietic Activity", Proc. Soc. Expt.
 Biol. Med., 86:255-258 (1954) -----

-

Gorman C, et al., "High Efficiency DNA-mediated Transformation of Primate
 Cells", Science, 221: 551-553 (1983)-----

Gorman et al., "Expression of Recombinant Plasmids in Mammalian Cells Is
 Enhanced by Sodium Butyrate", Nucl. Acid Res., 11: 7631-7648 (1983) -----

Goto et al., "Production of Recombinant Human Erythropoietin in Mammalian
 Cells: Host-Cell Dependency of the Biological Activity of the Cloned
 Glycoprotein", Bio/Tech. 6, 67-71 (Jan. 1988) -----

Gough et al., "Molecular Cloning of cDNA Encoding a Murine Haematopoietic
 Growth Regulator, Granulocyte-Macrophage Colony Stimulating Factor", Nature,
 309, 763-767 (1984) -----

Gray et al., "Expression of Human Immune Interferon cDNA in E. Coli and
 Monkey Cells", Nature, 295, 503-508 (Feb. 11, 1982) -----

Green et al., "Conserved Primary Sequences of the DNA Terminal Proteins of
 Five Different Human Adenovirus Groups", Proc. Natl. Acad. Sci. (USA), 76(9):

4380-4384 (1979)-----

Grundmann et al., "Characterization of cDNA Coding for Human Factor XIIIa", P.N.A.S. (USA), 83, 8024-8028 (Nov. 1986) -----

Grunstein et al., "Colony Hybridization", Meth. in Enzym. 68, 379-389 (1979) -----

Grunstein et al., "Colony Hybridization: A Method for the Isolation of Cloned DNAs that Contain a Specific Gene", P.N.A.S. (USA), 72(10), 3961-3965 (Oct. 1975) -----

Gruss et al., "Expression of Simian Virus 40-rat Preproinsulin Recombinant in Monkey Kidney Cells Use of Preproinsulin RNA Processing Signals", Proc. Natl. Acad. Sci. (USA), 78: 133-137 (1981)-----

Gruss et al., "Simian Virus 40 Tandem Repeated Sequences as an Element of the Early promoter", Proc. Natl. Acad. Sci. (USA), 78: 943-947 (1981) -----

Gubler et al., "A Simple and Very Efficient Method for Generating cDNA Libraries", Gene, 25, 263-269 (1983) -----

Gurney et al., "Studies on Erythropoiesis. VI. Erythropoietin in Human Plasma", J. Lab. & Clin. Med., 50(4): 534-542 (1957)-----

Haddy, "Erythropoietin in Sickle Cell Disease", Am. Jour. Ped. Hematol./Oncol., 4(2), 191-196 (Summer 1982) -----

-

Haga et al., "Plasma Erythropoietin Concentrations During the Early Anemia of Prematurity", Acta. Pediatr. Scand., 72, 827-831 (1983) -----

Hagiwara et al., "Erythropoietin Production in a Primary Culture of Human Renal Carcinoma Cells Maintained in Nude Mice", Blood, 63(4), 828-835 (Apr. 1984) ---

Hambley et al., "Erythropoietin: an Old Friend Revisited", BMJ, 300 : 621-622, (1990)-----

Hamer et al., "Expression of the Chromosomal Mouse β -globin Gene Cloned in SV40", Nature, 281, 35-40 (Sep. 6, 1979) -----

Hamer et al., "SV40 Recombinants Carrying Rabbit β -globin Gene Coding

Sequences", Cell, 17: 725-735 (1979)-----

Hamer et al., "A Mouse Globin Gene Promoter is Functional in SV40", Cell, 21, 697-708 (Oct. 1980) -----

Hammond et al., "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma", Ann. N.Y. Acad. Sci., 149, 516-527 (1968) -----

Hammond et al., "Paraneoplastic Erythrocytosis and Ectopic Erythropoietins", Ann. N. Y. Acad. Sci., 230: 219-27 (1974)-----

Hanahan et al., "Plasmid Screening at High Colony Density", Gene, 10, 63-67 (1980) -----

Hartman et al., "Human Influenza Virus Hemagglutinin is Expressed in Monkey Cells Using Simian Virus 40 Vectors", Proc. Natl. Acad. Sci. (USA), 79, 233-237 (1982) -----

Hauser et al., "Inducibility of Human .beta.-interferon in Mouse L-cell Clones", Nature, 297, 650-654 (Jun. 24, 1982) -----

Haynes et al., "Constitutive, Long-term Production of Human Interferons by Hamster Cells Containing Multiple Copies of a Cloned Interferon Gene", Nucleic Acids Research, 11(3), 587-607 (1983) -----

Haynes et al., "Production of a Glycosylated Human Protein by Recombinant DNA Technology", Proc. Takeda Sci. Found. Symp. Biosci., 111-29 (1983) -----

Hellmann et al., "Familial Erythrocytosis with Over-production of Erythropoietin", Clin. Lab. Haemat., 5, 335-342 (1983) -----

Hewick et al., "A Gas-Liquid Solid Phase Peptide and Protein Sequenator", J. Biol. Chem., 256, 7990-7997 (Aug. 1981)-----

Henry et al., "Clinical Use of Erythropoietin", Curr. Opin. Hematol., 2 (2): 118-124, (1995) -----

Higashi et al., "Structure and Expression of a Cloned cDNA for Mouse Interferon-.beta" -----

J. Biol. Chem., 258(15):9522-9529 (1983) -----

Hokke et al., "Sialylated Carbohydrate Chains of Recombinant Human Glycoproteins Expressed in Chinese Hamster Ovary Cells Contain Traces of N-glycolyneuraminic Acid", FEBS Letters, 275, 9-14 (1990)-----

Horowitz et al., "Expression of Chimeric Genes in the Early Region of SV40", Mol. and Appl. Genet., 2: 147-159 (1983)-----

Howley et al., "Molecular Characterization of Papilloma Virus", Cold Spring Harbor Conf. Cell Proliferation, 7: 233-247genomes (1980)-----

Hsiung et al., "Efficient Production of Hepatitis B Surface Antigen Using Bovine Papilloma Virus-metallothionein Vector", Mol. and Appl. Genet., 2: 497-506 (1987) -----

Hu et al., "DNA Sequence Required for Initiation of Transcription in Vitro from the Major Late Promoter of Adenovirus 2", Proc. Natl. Acad. Sci. (USA), 78: 820-824 (1981) -----

Huang et al., "Identification of Human Erythropoietin Receptor", Am. Soci. of Biological Chemists, Am. Assoc. of Immunologists, Fed. Pract. (USA) 43(7) Abst. 2770, p. 1891 (1984) -----

Huang et al., "Characterization of Human Erythropoietin cDNA Clones", Am. Soc. of Biological Chemists, Am. Assoc. of Immunologists, Fed. Pract. (USA), 43(6) Abst. 1795, p. 1724 -----

Imagawa et al., "Regulatory Elements of the Erythropoietin Gene", Blood, 77 (2) 278-285 (1991) -----

Imai et al., "Physicochemical and Biological Comparison of Recombinant Human Erythropoietin with Human Urinary Erythropoietin", J. Biochem, 107, 352-359 (1990) -----

Ismail et al., "An Opportunity to Intervene: Erythropoietin for the Treatment of Anaemia in Pre-dialysis Patients, Nephrol. Dial. Transplant., 13 (1): 14-17 (1998)

Itakura et al., "Synthesis and Use of Synthetic Oligonucleotides", Ann. Rev.

Biochem., 53, 323-356 (1984) -----

-

Jacobs et al., "Isolation and Characterization of Genomic and cDNA Clones of Human Erythropoietin", Nature, 313, 806-809 (Feb. 28, 1985) -----

Jacobsen et al., "Relative Effectiveness of Phenylhydrazine Treatment and Hemorrhage in the Production of an Erythropoietic Factor", Blood, 11:937-945 (1956) -----

Jacobson et al., "Role of the Kidney in Erythropoiesis", Nature, 179:633-634 (Mar 23, 1957) -----

Jaye et al., "Isolation of Human Anti-haemophilic Factor IX cDNA Clone Using a Unique 52-Base Synthetic Oligonucleotide Probe Deduced from the Amino Acid Sequence of Bovine Factor IX", Nucleic Acids Res. 11(8), 2325-2335 (1983) -----

Jelkman et al., "Extraction of Erythropoietin from Isolated Renal Glomeruli of Hypoxic Rats", Exp. Hematol., 11(7), 581-588 (Aug. 1983) -----

Johnston et al., "Rapid Spontaneous Dihydrofolate Reductase Gene Amplification Shown by Fluorescence-activated Cell Sorting", Proc. Natl. Acad. Sci. (USA), 80: 3711-3715 (1983)-----

-

Kajimura et al., "Cloning the Heavy Chain of Human HLA-DR Antigen Using Synthetic Oligodeoxyribonucleotides as Hybridization Probes", DNA, 2(3), 175-182 (1983) -----

Karin et al., "Expression and Regulation of a Human Metallothionein Gene Carried on an Autonomously Replicating Shuttle Vector", Proc. Natl. Acad. Sci. (USA), 80: 4040-4044 (1983)-----

Karn et al., "Novel Bacteriophage .lambda. Cloning Vector", P.N.A.S. (USA), 77, 5172-5176 (Sep. 1980) -----

-

Katsuoka et al., "Erythropoietin Production in Human renal Carcinoma Cells

Passaged in Nude Mice and in Tissue Culture", Gann, 74, 534-541 (Aug. 1983) --
 Katz et al., "Studies on the Site of Production of Erythropoietin", Ann. N.Y. Acad.
 Sci., 149: 120-127 (1968) -----
 Kaufman et al., "Amplified Dihydrofolate Reductase Genes in Instable
 Methotrexate-resistant Cells are Associated with Double Minute Chromosome",
 Proc. Natl. Acad. Sci. (USA), 76: 5669-5673 (1979)-----
 Kaufman et al., "Construction of a Modular Dihydrofolate Reductase cDNA
 Gene: Analysis of Signals Utilized for Efficient Expression", Mol. Cell. Biol., 2:
 1304-1319 (1982) -----
 Kaufman et al., "Amplification and Expression of Sequences Cotransfected with
 a Modular Dihydrofolate Reductase Complementary DNA Gene", J. Mol. Biol.,
 159, 601-621 (1982) -----
 Kaufman et al., "Expression and Amplification of DNA Introduced into
 Mammalian Cells", Gene Amplification, pp. 245-250, RT Schimke, Cold Spring
 Harbor, New York, New York (1982) -----
 Kaufman et al., "Evolution of Chromosomal Regions Containing Transfected and
 Amplified Dihydrofolate Reductase Sequences", Mol. Cell. Biol., 3: 699-711
 (1983) -----
 Kaufman R et al., "Coamplification and Coexpression of Human Tissue-Type
 Plasminogen Activator and Murine Dihydrofolate Reductase Sequences in
 Chinese Hamster Ovary Cells", Mol. and Cell. Biol., 5 (7) 1750-9 (1985) -----
 Kawai et al., "New Procedure for DNA Transfection with Polycation and Dimethyl
 Sulfoxide", Mol. Cell. Biol., 4(6): 1172-1174 (1984)-----
 Kennell, "Principles and Practices of Nucleic Acid Hybridization", Prog. Nucl. Acid
 Res. Mol. Biol., 11, 259-301 (1971) -----
 Kieny et al., "Expression of Rabies Virus Glycoprotein from a Recombinant
 Vaccinia Virus", Nature, 312, 163-166 (1984) -----
 Kingston et al., "Regulation of Transcription of the Adenovirus EII Promoter by

Ela Gene Products: Absence of Sequence Specificity", Mol. Cell. Biol., 4(10): 1970-1977 (1984)-----

Koeller, "Clinical Guidelines for the Treatment of Cancer Related Anemia", Pharmacotherapy, 18 (1): 156-169 (1998)-----

Konrad, "Applications of Genetic Engineering to the Pharmaceutical Industry", Ann. N.Y. Acad. Sci., 413, 12-22 (1983) -----

Konwalinka et al., "A Miniaturized Agar Culture System for Cloning Human Erythropoietic Progenitor Cells" , Exp. Hematol., 12, 75-79 (1984) -----

Kornblihtt et al., "Isolation and Characterization of cDNA Clones for Human and Bovine Fibronectins", P.N.A.S. (USA), 80, 3218-3222 (June 1983) -----

Krane, "The Role of Erythropoietin in the Anemia of Chronic Renal Failure", Henry Ford Hosp. Med. J., 31(3), 177-181 (1983) -----

Krantz, "Erythropoietin", Blood, 77 (3): 419-434 -----

Krystal, "A Simple Microassay for Erythropoietin Based on ³H-Thymidine Incorporation into Spleen Cells from Phenylhydrazine Treated Mice", Exp. Hematol., 11(7), 649-660 (Aug. 1983) -----

Krystal et al., "CM Affi-gel Blue Chromatography of Human Urine: A Simple One-step Procedure for Obtaining Erythropoietin Suitable for In Vitro Erythropoietic Progenitor Assays", British J. Haematol., 58: 533-546 (1984) -----

-

Kuhn et al., "Gene Transfer, Expression, and Molecular Cloning of the Human Transferrin Receptor Gene", Cell, 37, 95-103 (1984) -----

Kurachi et al., "Isolation and Characterization of a cDNA Coding for Human Factor IX", P.N.A.S. (USA), 79, 6461-6464 (Nov. 1982) -----

Kuratowska et al., "Studies on the Production of Erythropoietin by Isolated Perfused Organs", Blood, 18:527-534 (1961) -----

Kurtz, "A New Candidate for the Regulation of Erythropoiesis: Insulin-like Growth Factor I", FEBS Letters, 149(1), 105-108 (Nov. 1982)-----

-

Kurtz, "Hormonal Inducibility of Rat 2u Globulin Genes in Transfected Mouse Cells", *Nature*, 291: 629-631 (1981)-----

Lafferty et al., "Ultrastructural, Immunocytochemical Localization of Presumptive Erythropoietin Binding Sites on Developing Erythrocytic Cells of Normal Human Bone Marrow", *J. Hystochem. Cytochem.*, 29(1): 49-56 (1981) -----

Lai et al., "Ovalbumin is Synthesized in Mouse Cells Transformed with the Natural Chicken Ovalbumin Gene", *P.N.A.S. (USA)*, 77(1), 244-248 (Jan. 1980)

-

Lai et al., "Structural Characterization of Human Erythropoietin", *J. of Biol. Chem.*, 261, 3116-3121 (Mar. 5, 1986) -----

Lai, "Technical Improvements in Protein Microsequencing", *Analytica Chimica Acta*, 163, 243-248 (1984) -----

Lange et al., "Application of Erythropoietin Antisera to Studies of Erythropoiesis", *Ann. N.Y. Acad. Sci.*, 149:281-291 (1968) -----

Lange et al., "Antisera to Erythropoietin: Partial Characterization of Two Different Antibodies", *J. Lab. & Clin. Med.*, 73(1): 78-90 (1969)-----

Lappin et al., "The Effect of Erythropoietin and Other Factors on DNA Synthesis by Mouse Spleen Cells", *Exp. Hematol.*, 11(7), 661-666 (Aug. 1983) -----

Lasky et al., "Production of an HSV Subunit Vaccine by Genetically Engineered Mammalian Cell Lines", *Modern Approaches to Vaccines*, pp. 189-194, Chanock et al., Eds. Cold Spring Harbor Lab. (1984) -----

Lathe, "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data", *J. Mol. Biol.*, 183, 1-12 (1985) -----

Laub et al., "Expression of the Human Insulin Gene and cDNA in a Heterologous Mammalian System", *J. Biol. Chem.*, 258(10), 6043-6050 (May 25, 1983) -----

Laub et al., "Synthesis of Hepatitis B Surface Antigen in Mammalian Cells: Expression of the Entire Gene and the Coding Region", *Virol.*, 48(1):271-280 (1983) -----

Lavi, "Carcinogen-mediated Amplification of Viral DNA Sequences in Simian

Virus 40-Transformed Chinese Hamster Embryo Cells", Proc. Natl. Acad. Sci. (USA), 78: 6144-6148 (1981)-----

Law et al., "A Stable Bovine Papillomavirus Hybrid Plasmid that Expresses a Dominant Selective Trait", Mol. Cel. Biol., 3(11): 2110-2115 (1983) -----

Lee et al., "Glucocorticoids Regulate Expression of Dihydrofolate Reductase cDNA in Mouse Mammary Tumour Virus Chimeric Plasmids", Nature, 294: 228-232 (1981)-----

Lee-Huang, "The Erythropoietin Gene", Oncogenes, Genes and Growth Factors, Chap. 7, pp. 199-222, Gordon Garaff, Ed., John Wiley & Sons, Boston, Massachusetts (1987) -----

Lee-Huang, "Cloning of Human Erythropoietin", Biophysical J., 45(Part 2 of 2), ABT. M-PM-A12, p. 30a (1984) -----

Lee-Huang, "Monoclonal Antibodies to Human Erythropoietin", Abstract No. 1463, Fed. Proc., 41, 520 (1982) -----

Lee-Huang, "A New Preparative Method for Isolation of Human Erythropoietin with Hydrophobic Interaction Chromatography", Blood, 56(4), 620-624 (Oct. 1980) -----

Lee-Huang, "Cloning and Expression of Human EPO cDNA in E. Coli", P.N.A.S.(USA), 81, 2708-2712 (May 1984) -----

Levine et al., "Perioperative Recombinant Human Erythropoietin", Surgery 106 (2): 432-438, (1989) -----

Lewin, Genes, p. 307., John Wiley & Sons, Boston, Massachusetts (1983) -----

Lewis et al., "Selective Amplification of Polymorphic Dihydrofolate Reductase Gene Loci in Chinese Hamster Lung Cells", Proc. Natl. Acad. Sci. (USA), 79: 6961-6965 (1982)-----

Lewis et al., "Gene Amplification Accompanies Low Level Increases in the Activity of Dihydrofolate Reductase in Antifolate-resistant Chinese Hamster Lung Cells Containing Abnormally Banding Chromosomes", J. Cell. Biol., 94: 418-424

(1982)-----

Lin et al., "Cloning and Expression of the Human Erythropoietin Gene", Proc. Natl. Acad. Sci. (USA), 82, 7580-7584 (Nov. 1985) -----

Lin et al., "Monkey Erythropoietin Gene: Cloning, Expression and Comparison with the Human Erythropoietin Gene", Gene, 44, 201-209 (1986) -----

Lin et al., "Cloning of the Monkey EPO Gene", Abstract, J. Cell. Bioch., Suppl. 8B, p. 45 (Mar. 31-Apr. 24, 1984) -----

Lin et al., "Cloning and Expression of Monkey and Human Erythropoietin", Exp. Hematol. 12, 357 (1984) -----

Linman et al., "Studies on the Erythropoietic Effects of Hyperbaric Hyperoxia", Ann. N.Y. Acad. Sci., 149: 25-33 (1968)-----

Lipschitz et al., "Effect of Age on Hematopoiesis in Man", Blood, 63(3), 502-509 (Mar. 1983) -----

Liu Ch et al., "Direct Expression of Hepatitis B Surface Antigen in Monkey Cells from an SV40 Vector", DNA, 1: 213-221 (1982)-----

Lusky et al., "Inhibition of SV40 Replication in Simian Cells by Specific pBR DNA Sequences", Nature, 293: 79-81 (1981)-----

Maniatis et al., "The Isolation of Structural Genes from Libraries of Eucaryotic DNA", Cell, 15, 687-701 (Oct. 1978) -----

-

Maniatis et al., "Molecular Cloning, a Laboratory Manual", pp. 5, 197-199, 392-393, 479-487, 493-503 Cold Springs Harbor, N.Y. (1982) -----

Maxam et al., "Sequencing End Labeled DNA with Base-Specific Chemical Cleavages", Methods in Enzymol., 65, 499-560 (1980) -----

Macdougall et al., "Pharmacokinetics of Recombinant Human Erythropoietin in Patients on Continous Ambulatory Peritoneal Dialysis", The Lancet, 425-427 (February 25, 1989)-----

Macdougall et al., "Treating Renal Anaemia with Recombinant Huamn

Erythropoietin: Practical Guidelines and a Clinical Algorithm", Br. Med. J., 300 (10): 655-659 (1990)-----

Macdougall, "Meeting the Challenges of the New Millennium: Optimizing the Use of Recombinant Human Erythropoietin" Nephrol. Dial. Transplant., 13 (2):23-27 (1998)-----

MacMillan et al., "Recombinant Human Erythropoietin in Children with Cancer", J. Pediatr. Hematol. Oncol., 20 (3): 187-189 (1998)-----

Maroteaux et al., "Sequences Involved in the Regulated Expression of the Human Interferon- 1 Gene in Recombinant SV40 DNA Vectors Replicating in Monkey Cells", The EMBO J. 1983, 2(3): 325-332-----

McCormick et al., "Regulated Expression of Human Interferon Genes In Chinese Hamster Ovary Cells", DNA, 2(1): 86 Abst 86 (1983) -----

McCormick et al., "Inducible Expression of Amplified Human Beta Interferon Genes in CHO Cells", Mol. Cell. Biol., 4(1):166-172 (Jan. 1984) -----

McDonald et al., "Cloning, Sequency, and Evolutionary Analysis of the Mouse Erythropoietin Gene", Mol. Cell. Biol., 6(3): 842-848 -----

McGonigle et al., "Erythropoietin Deficiency and Inhibition of Erythropoiesis in Renal Insufficiency", Kidney Intl., 25(2), 437-444 (1984) -----

Meier et al., "Alpha.sub.1 -and Beta.sub.2 -Adrenergic Receptors Co-Expressed on Cloned MDCK Cells are Distinct Glycoproteins", Biochem. & Biophys. Res. Comm., 118(1), 73-81 (1984) -----

Mellon et al., "Identification of DNA Sequences Required for Transcription of the Human .alpha.1-Globin Gene in a New SV40 Host-Vector System", Cell, 27, 279-288 (Dec. 1981) -----

Mellor et al., "Expression of Murine H-2K.sup.b Histocompatibility Antigen in Cells Transferred with Cloned H-2 Genes", Nature, 298:529-534 (Aug. 1982) -----

Messing, "New M13 Vectors for Cloning", Methods in Enzymology, 101, 20-78

(1983) -----
 "Methods in Yeast Genetics", P. 62, Cold Spring Harbor Lab., Cold Spring Harbor, New York (1983) -----
 Miller et al., "Plasma Levels of Immunoreactive Erythropoietin after Acute Blood Loss in Man", Brit. J. Haematol., 52, 545-549 (1982) -----
 Mirand, "Extra-renal and Renal Control of Erythropoietin Production", Ann. N.Y. Acad. Sci., 149:94-106 (1968) -----
 Mirand et al., "Current Studies on the Role of Erythropoietin on Erythropoiesis", Ann. N.Y. Acad. Sci., 77:677-702 (1959)-----
 Mishina et al., "Expression of Functional Acetylcholine Receptor from Cloned cDNA", Nature, 307: 604-608 (1984)-----
 Mitrani-Rosenbaum et al., "Inducible Expression of the Human Interferon 1 Gene Linked to a Bovine Papilloma Virus DNA a Vector and Maintained Extrachromosomally in Mouse Cells", Mol. Cell. Biol., 3: 233-240 (1983) -----
 Miyake et al., "Purification of Human Erythropoietin", J. Biol. Chem., vol. 252(15), 5558-5564 (Aug. 1977) -----
 Mladenovic et al., "Anemia of Chronic Renal Failure (CRF) in the Sheep: Response to Erythropoietin (EP) In Vivo and In Vitro", Blood, 58(5), Suppl. 1, 99a (1981) -----
 Moia et al., "Improvement in the Haemostatic Defect of Uraemia after treatment with Recombinant Human Erythropoietin", The Lancet, 1227-1229 (November 28, 1987) -----
 Moreau et al., "The SV40 72 Base Repair Repeat has a Striking Effect on Gene Expression both in SV40 and Other Chimeric Recombinants", Nucl. Acid Res., 9: 6047-6067 (1981) -----
 Moriarty et al., "Expression of the Hepatitis B Virus Surface Antigen Gene in Cell Culture by Using a Simian Virus 40 Vector", P.N.A.S. (USA), 78(4):2606-10 (Apr. 1981) -----

Mujovic et al., "The Effect of Indomethacin on Erythropoietin Production in Dogs Following Renal Artery Constriction. The Possible Role of Prostaglandins in the Generation of Erythropoietin by the Kidney", J. Pharmacol. Exp. Ther., 191: 575-581 (1974) -----

Mulligan et al., "Factors Governing the Expression of a Bacterial Gene in Mammalian Cells", Mol. Cell. Biol., 1: 449-459 (1981) -----

Mulligan et al., "Synthesis of Rabbit β -globin in Cultured Monkey Kidney Cells Following Infection with a SV40 β -globin Recombinant Genome", Nature, 277: 108-114 (1979) -----

Mulligan et al., "Expression of a Bacterial Gene in Mammalian Cells", Science, 209: 1422-1427 (1980) -----

-

Mulligan et al., "Selection for Animal Cells that Express the Escherichia Coli Gene Coding for Xanthine-guanine Phosphoribosyltransferase", Proc. Natl. Acad. Sci. (USA), 78: 2072-2076 (1981) -----

Murphy et al., "The Role of Glycoprotein Hormones in the Regulation of Hematopoiesis" -----

-

Acta. Haematologica Japonica, 46(7), 1380-1396 (Dec. 1983) -----

Murray et al., "Construction and Use of a Dominant, Selectable Marker: a Harvey Sarcoma Virus-dihydrofolate Reductase Chimera", Mol. Cel. Biol., 3(1): 32-43 (1983) -----

Myers et al., "Construction and Analysis of Simian Virus 40 Origins Defective in Tumor Antigen Binding and DNA Replication", P.N.A.S. (USA), 77, 6491-6495 (Nov. 1980) -----

Naets, "The Role of the Kidney in Erythropoiesis", J. Clin. Invest., 39:102-110 (1960) -----

Nakao et al., "Erythropoiesis in Anephric or Kidney Transplanted Patients", Israel J. Med. Sci., 7:986-989 (Jul.-Aug. 1971) -----

Nathan et al., "Erythropoietin and the Regulation of Erythropoiesis", N. England J. of Med., 308(9), 520-522 (Mar. 3, 1983) -----

Naughton et al., "Evidence for an Erythropoietin-Stimulating Factor in Patients with Renal and Hepatic Disease", Acta. Haemat., 69, 171-179 (1983) -----

Naughton et al., "Evidence for a Hepatic-Renal Antagonism in the Production of Hepatic Erythropoietin", Ann. Clin. Lab. Sci., 13(5), 432-438 (1983) -----

Nayak et al., "Characterization of Influenza Virus Glycoproteins Expressed from Cloned cDNAs in Prokaryotic and Eukaryotic Cells", Modern Approaches To Vaccines, pp. 165-172, Chanock et al., eds., Cold Spring Harbor Lab. (1984) -----

Nielsen et al., "Erythropoietin b-D-galactosidase. The Generation, Purification and Use of Fusion Protein", J. Immunol. Meth., 111: 1-9 (1988) -----

-

Nigg et al., "Immunofluorescent Localization of the Transforming Protein of Rous Sarcoma Virus with Antibodies against a Synthetic src Peptide", P.N.A.S. (USA), 79, 5322-5326 (Sep. 1982) -----

Nimtz et al., "Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells", Eur. J. Biochem, 213, 39-56 (1993) ---

Nunberg et al., "Amplified Dihydrofolate Reductase Genes are Localized to a Homogeneously Staining Region of a Single Chromosome in a Methotrexate-resistant Chinese Hamster Ovary Cell Line", Proc. Natl. Acad. Sci. (USA), 75: 5553-5556 (1978)-----

O'Hare et al., "Transformation of Mouse Fibroblast to Methotrexate Resistance by a Recombinant Plasmid Expressing a Prokaryotic Dihydrofolate", Natl. Acad. Sci. (USA), 78: 1527-1531 (1981)-----

Ogle et al., "Production of Erythropoietin In Vitro: A Review", In Vitro, 14(11), 945-949 (1978) -----

Okayama et al., "A cDNA Cloning Vector that Permits Expression of cDNA Inserts in Mammalian Cells", Mol. Cell. Biol., 3: 280-289 (1983)-- -----

Ohno et al., "Inducer-responsive Expression of the Cloned Human Interferon 1

Gene Introduced into Cultured Mouse Cells", Nucl. Acid. Res., 10(3): 967-977 (1982)-----

Osterborg, "Recombinant Human Erythropoietin (rHuEPO) Therapy in Patients with Cancer Related Anaemia: What Have We Learned?", Med. Oncol., 15 (Suppl. 1): 47-49 (1998)-----

Pankratz et al., "A Simple 3-Step Procedure for Purifying Baboon Urinary Erythropoietin to Apparent Homogeneity", Exp. Hematol., 11, Supp. 14, Abst. 102 (1983) -----

Papayannopoulou et al., "On the In Vivo Action of Erythropoietin: A Quantitative Analysis", J. of Clin. Investigation, 51, 1179-1185 (1972) -----

Parekh et al., "N-Glycosylation and In Vitro Enzymatic Activity of Human Recombinant Tissue Plasminogen Activator Expressed in Chinese Hamster Ovary Cells and a murine Cell Line", Biochemistry, 28, 7670-7679 (1989) -----

Parker et al., "Regulation of Simian Virus 40 Transcription: Sensitive Analysis of the RNA Species Present Early in Infections by Virus or Viral DNA", J. Virol., 31(2): 360-369 (1979)-----

Pavlakakis et al., "Regulation of a Metallothionein-growth Hormone Hybrid Gene in Bovine Papilloma Virus", Proc. Natl. Acad. Sci. (USA), 80: 397-401 (1983) -----

Pavlovic-Kentera et al., "Effects of Prostaglandin Synthetase Inhibitors, Salt Overload and Renomedullary Dissection on the Hypoxia Stimulated Erythropoietin Production in Rats", Exp. Hematol., 8(Supp. 8), 283-291 (1980) --

Pennathur-Das et al., "Evidence for the Presence of CFU-E with Increased In Vitro Sensitivity to Erythropoietin in Sick Cell Anemia", Blood, 63(5), 1168-71 (May 1984) -----

Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, Boston, Massachusetts (1984) -----

Pitha et al., "Induction of Human .beta.-interferon Synthesis with Poly (rl.cndot.rC) in Mouse Cells Transfected with Cloned cDNA Plasmids", P.N.A.S.

(USA), 79, 4337-4341 (Jul. 1982) -----

Powell et al., "Human Erythropoietin Gene: High Level Expression in Stably Transfected Mammalian Cells and Chromosome Localization", Proc. Natl. Acad. Sci. (USA), 83, 6465-6469 (Sep. 1986) -----

Quelle et al., "High-level Expression and Purification of a Recombinant Human Erythropoietin Producing a Baculovirus Vector", Blood, 74: 652-657 (1989) -----

Quelle et al., "Phosphorylatable and Epitope-Tagged Human Erythropoietins: Utility and Purification of Native Baculovirus-Derived Forms", Protein Expression and Purification 3, 461-469 (1992)-----

Radtke et al., "Serum Erythropoietin Concentration in Chronic Renal Failure: Relationship to Degree of Anemia and Excretory Renal Function", Blood, 54 (4): 877-884 (1979)-----

-

Ramabhadran et al., "Synthesis and Glycosylation of the Common .alpha. Subunit of Human Glycoprotein Hormones in Mouse Cells", Proc. Natl. Acad. Sci. (USA), 81, 6701-6705 (1984) -----

Rambach et al., "Acid Hydrolysis of Erythropoietin", Proc. Soc. Exp. Biol., 99, 482-483 (1958) -----

Recny et al., "Structural Characterization on Natural Human Urinary and Recombinant DNA-derived Erythropoietin", Biol. Chem., 262 (35): 17156-17163 (1987) -----

Recormon® Products Monograph, Renal Anaemia, Boehringer Mannheim GmbH--

Reddy et al., "Nucleotide Sequence Analysis of the Proviral Genome of Avian Myelocytomatosis Virus (MC29)", Proc. Natl. Acad. Sci. (USA), 80: 2500-2504 (1983) -----

Reilly et al., "Use of Synthetic Oligonucleotides to Clone Genomic DNA: Isolation of a tRNA.sup.Phe Gene from Mouse", DNA, 1:192 (1982) -----

Reissmann et al., "Erythropoietin Formation in Isolated Kidneys and Liver", Erithropoiesis, 71-77 (1962) -----

Rigby, "Expression of Cloned Genes in Eukaryotic Cells Using Vector Systems Derived from Viral Replicons", Genetic Engineering, R. Williamson, Ed., 3:83-140, Academic Press, London, England (1982) -----

Rigby , "Review Article: Cloning Vectors Derived from Animal Viruses", J. Gen. Virol., 64: 255-266 (1983) -----

Riggs et al., "Synthetic DNA and Medicine", Am. J. Hum. Genet., 31, 531-538 (1979) -----

Ringold et al., "Co-Expression and Amplification of Dihydrofolate Reductase cDNA and the Escherichia coli XGPRT Gene in Chinese Hamster Ovary Cells", J. Mol. & Appl. Genetics, 1(3), 165-175 (1981) -----

Roh et al., "Plasma Disappearance of I.sup.125 labeled Human Urinary Erythropoietin in Rabbits", Fed. Proc., 29(2), 782 Abst. 3030 (1970) -----

-
Rose et al., "Expression from Cloned cDNA of Cell-Surface Secreted Forms of the Glycoprotein of Vesicular Stomatitis Virus in Eucaryotic Cells", Cell, 30, 753-762 (1982) -----

Rosso et al., "Use of Erithropoietin in Oncology", Tumori., 83 (4 Suppl.2): 26-30, (1997) -----

Roth et al., "Influenza Virus Hemagglutinin Expression Is Polarized in Cells Infected with Recombinant SV40 Viruses Carrying Cloned Hemagglutinin DNA", Cell, 33, 435-443 (1983) -----

Rothmann et al., "Erythropoietin-Dependent Erythrocytosis Associated with Hepatic Angiosarcoma", J. Surg. Oncol., 20, 105-108 (1982) -----

Saito et al., "Translation of Human Erythropoietin-mRNAs", Exp. Hematol., 11(14), 228 (1983) -----

Saito et al., "In Vitro Assay of Erythropoietin: Simple Determination in a Small Amount of Human Serum Samples", Jap. J. Med., 23(1), 16-21 (Feb. 1984) -----

Sakata et al., "Plasma Erythropoietin Assay by a Fetal Mouse Liver Cell Culture Method with Special Reference to Effective Elimination of Erythroid Colony

Inhibitor(s) in Plasma", Exp. Hematol., 15: 226-233 (1987) -----

-

Sambrook et al., "Expression of Proteins on the Cell Surface Using Mammalian Vectors", Experimental Manipulation of Gene Expression, pp. 225-246, Academic Press, London, England (1983) -----

-

Sanders et al., "Amplification and Cloning of the Chinese Hamster Glutamine Synthetase Gene", The EMBO J., 3: 65-71 (1984)-----

Sanger et al., "DNA Sequencing with Chain-terminating Inhibitors", P.N.A.S. (USA), 74, 5463-5467 (Dec. 1977) -----

-

Sarver et al., "Bovine Papilloma Virus Deoxyribonucleic Acid: A Novel Eukaryotic Cloning Vector", Mol. Cell. Biol., 1: 486-496 (1981)-----

Sarver et al., "Transformation and Replication in Mouse Cells of a Bovine Papillomavirus-pML2 Plasmid Vector that Can Be Rescued in Bacteria", Proc. Natl. Acad. Sci. (USA), 79: 7147-7151 (1982)-----

Sasaki, "Isolation of Erythropoietin by Monoclonal Antibody", Biomed. Biochim. Acta., 42(11/12), S202-206 (1983) -----

Sasaki et al., "Carbohydrate Structure of Erythropoietin Expressed in Chinese Hamster Ovary Cells by a Human Erythropoietin cDNA", J. Biol. Chem., 262(25), 12059-12070 (Sep. 5, 1987) -----

Sasaki et al., "Site-specific Glycosilation of Human Recombinant Erythropoietin: Analysis of Glycopeptides of Peptides at Each Glycosilation Site by Fast Atom Bombardment Mass Spectrometry", Bioch.,27: 8618-8626 (1988)-----

Saveria Campo et al., "Transcriptional Control Signals in the Genome of Bovine Papillomavirus Type 1", Nature, 303: 77-80 (1983)-----

Scahill et al., "Expression and Characterization of the Product of a Human Immune Interferon cDNA Gene in Chinese Hamster Ovary Cells", Proc. Natl. Acad. Sci. (USA), 80, 4654-4658 (1983)-----

Schaffner W, "Direct Transfer of Cloned Genes from Bacteria to Mammalian Cells", Proc. Natl. Acad. Sci., 77: 2163-2167 (1980) -----

Schimke et al., "Chromosomal and Extrachromosomal Localization of Amplified Dihydrofolate Reductase Genes in Cultured Mammalian Cells", Cold Spring Harbor Symp. Quant. Biol., 45: 785-797 (1981)-----

Schimke, "Gene Amplification in Cultured Animal Cells", Cell, 37: 705-713 (1984)

Seeburg et al., "Synthesis of Growth Hormone by Bacteria", Nature, 276, 795-798 (Dec. 1978) -----

Shahidi, "Androgens and Erythropoiesis", N. England J. of Med., 289, 72-80 (Jul. 12, 1973) -----

Sherwood et al., "Erythropoietin Titers in Sickle Cell Disease and Chronic Renal Failure", Blood, 58: 49^a (1981)-----

Sherwood et al., "Extraction of Erythropoietin from Normal Kidneys", Endocrinology, 103(3), 866-870 (1978) -----

Sherwood et al., "A Radioimmunoassay for Erythropoietin", Blood, 54(4), 885-893 (Oct. 1979) -----

Sherwood et al., "Erythropoietin Titers in Sickle Cell Disease and Chronic Renal Failure", Blood, 58 (1), Supp. 1, Abstract 105 (1981)-----

Shiramizu et al., "Human Renal Carcinoma Cells Secreting Erythropoietin In Vivo and In Vitro", Blood, 78(10), Supp. 1 (Nov. 15, 1991) -----

Shoemaker et al., "Murine Erythropoietin Gene: Cloning, Expression, and Human Gene Homology", Mol. Cell. Biol., 6 (3): 849-858 -----

Schumperli et al., "Efficient Expression of Escherichia Coli Galactokinase Gene in Mammalian Cells", Proc. Natl. Acad. Sci. (USA), 79: 257-261 (1982) -----

Siddiqui, "NOTE: Expression of Hepatitis B Virus Surface Antigen Gene in Cultured Cells by Using Recombinant Plasmid Vectors", Mol. Cell. Biol., 3: 143-147 (1983) -----

Simonsen et al., "Isolation and Expression of an Altered Mouse Dihydrofolate

Reductase cDNA", Proc. Natl. Acad. Sci. (USA), 50: 2495-2499 (1983) -----

Singer-Sam et al., "Isolation of a cDNA Clone for Human X-linked 3-phosphoglycerate Kinase by Use of a Mixture of Synthetic Oligodeoxyribonucleotides as a Detection Probe", P.N.A.S. (USA), 80, 802-806 (Feb. 1983) -----

Smith et al., "Construction and Characterization of an Infectious Vaccinia Virus Recombinant that Expresses the Influenza Hemagglutinin Gene and Induces Resistance to Influenza Virus Infection in Hamsters", Proc. Natl. Acad. Sci. (USA), 80, 7155-7159 (1983) -----

Smith et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector", Mol. Cell. Biol., 3(12): 2156-2165 (1983) -----

Smith Dordal et al., "The Role of Carbohydrate in Erythropoietin Action", Endocrinology, 116 (6): 2293-2299 (1985) -----

Sood et al., "Isolation and Partial Nucleotide Sequence of a cDNA Clone for Human Histocompatibility Antigen HLA-B by Use of an Oligodeoxynucleotide Primer", Proc. Natl. Acad. Sci. (USA), 78: 616-620 (1981) -----

Southern et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter", J. Mol. Appl. Genet., 1(4), 327-341 (1982) -----

Southern, "Detection of Specific Sequences Among DNA Fragments Separated by Gel Electrophoresis", J. Mol. Biol., 98, 503-517 (1975) -----

Spellman et al., "Carbohydrate Structure of Recombinant Soluble Human CD4 Expressed in Chinese Hamster Ovary Cell", Biochemistry, 30(9), 2395-2406 (1991) -----

Spellman et al., "Carbohydrate Structure of Human Tissue Plasminogen Activator Expressed in Chinese Hamster Ovary Cells", J. of Biol. Chem., 264(24), 14100-14111 (Aug. 26, 1989) -----

Spivak, "Erythropoietin: A Brief Review", Nephron, 52: 289-294 (1989)-----

Spivak et al., "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat", Blood, 73 (1): 90-99 (1989)-----

Stark et al., "Gene Amplification", Ann. Rev. Biochem., 53: 447-91 (1984) -----

-

Steinberg et al., "Erythropoietin Kinetics in Rats: Generation and Clearance", Blood, 67 (3): 646-649 (1986)-----

Stenlund et al., "Secretion of Hepatitis B Virus Surface Antigen from Mouse Cells Using an Extra-chromosomal Eucaryotic Vector", The EMBO J., 1983, 2(5): 669-673 -----

Stephenson et al., "Quantitative Assay Method for Erythropoietin In Vitro", Endocrinology, 88: 1519-1520 (1971) -----

Storring et al., "The International Standard for Recombinant DNA Derived Erythropoietin: Collaborative Study of Four Recombinant DNA Derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins", J. of Endo., 134, 459-84 (1992) -----

Stratowa et al., "Recombinant Retroviral DNA Yielding High Expression of Hepatitis B Surface Antigen", The EMBO J., 1(12): 1573-1578 (1982) -----

Subramani et al., "Expression of the Mouse Dihydrofolate Reductase Complementary Deoxyribonucleic Acid in Simian Virus SV 40 Vectors", Mol. Cell. Biol., 1: 854-864 (1981) -----

Sue et al., "Site-specific Antibodies to Human Erythropoietin Directed toward the NH.sub.2 -terminal Region", Proc. Nat. Acad. Sci. (USA), 80, 3651-3655 (1983) -

-

Suggs et al., "Use of Synthetic Oligodeoxyribonucleotide for the Isolation of Specific Cloned DNA Sequences", Developmental Biology Using Purified Genes, 683-693, D. Brown, Ed. (1981) -----

Suggs et al., "Use of Synthetic Oligonucleotides as Hybridization Probes: Isolation of Cloned cDNA Sequences for Human B.sub.2 -microglobulin", P.N.A.S. (USA), 78, 6613-6617 (1981) -----

- Sveda et al., "Functional Expression in Primate Cells of Cloned DNA Coding for the Hemagglutinin Surface Glycoprotein of Influenza Virus", *Pros. Natl. Acad. Sci. (USA)*, 78(10):5488-5492 (Sep. 1981) -----
- Sytowski et al., "The Biochemistry of Erythropoietin: An Approach to its Mode of Action", *Exp. Hematol.*, 8(Supp. 8), 52-63 (1980) -----
- Sytowski et al., "A Novel Radioimmunoassay for Human Erythropoietin Using a Synthetic NH.sub.2 -Terminal Polypeptide and Anti-Peptide Antibodies", *J. Immunol. Methods*, 69, 181-186 (1984) -----
- Szostak et al., "Hybridization with Synthetic Oligonucleotides", *Meth. in Enzymol.*, 68, 419-428 (1979) -----
- Takeuchi et al., "Relationship between Sugar Chain Structure and Biological Activity of Recombinant Human Erythropoietin Produced in Chinese Hamster Ovary Cells", *Proc. Natl. Acad. Sci. (USA)*, 86, 7819-7822 (Oct. 1989) -----
- Takeuchi, "Comparative Study of the Asparagine-linked Sugar Chains of Human Erythropoietin Purified from Urine and the Culture Medium of Recombinant Chinese Hamster Ovary Cells", *J. Biol. Chem.*, 263(8), 3657-3663 (Mar. 15, 1988) -----
- Tambourin et al., "Production of Erythropoietin-like Activity by a Murine Erythroleukemia Cell Line", *P.N.A.S. (USA)*, 80, 6269-6273 (1983) -----
- Taub et al., "An Improved Method for Preparing Large Arrays of Bacterial Colonies Containing Plasmids for Hybridization: In Situ Purification and Stable Binding of DNA on Paper Filters", *Chemical Abstracts*, 97(23), 164, Abstract No. 194002y (Dec. 12, 1982) -----
-
- Taub et al., "An Improved Method for Preparing Large Arrays of Bacterial Colonies Containing Plasmids for Hybridization: In Situ Purification and Stable Binding of DNA on Paper Filters", *Anal. Biochem.*, 126, 222-230 (1982) -----
- Testa et al., "Role of Purified Erythropoietin in the Amplification of the Erythroid Compartment", *Exp. Hematol.*, 8(Supp. 8), 144-152 (1980) -----

Tong et al., "The Formation of Erythrocyte Membrane Proteins during Erythropoietin-induced Differentiation", J. Biol. Chem., 256(24), 12666-12672 (Dec. 25, 1981) -----

Toole et al., "Molecular Cloning of a cDNA Encoding Human Antihaemophilic Factor", -----
Nature, 312, 342-347 (Nov. 8, 1984) -----

-
Tsuda et al., "Comparative Structural Study of N-Linked Oligosaccharides of Urinary and Recombinant Erythropoietins", Biochemistry, 27(15), 5646-5654 (1988) -----

Tsuda et al., "The Role of Carbohydrate in Recombinant Human Erythropoietin", Eur. J. Biochem., 188: 405-411 (1990) -----

-
Thummel et al., "Construction of Adenovirus Expression Vectors by Site-directed In Vivo Recombination", J. Mol. Appl. Genet., 1:435-446 (1982) -----

Thummel et al., "Translational Control of SV40 T Antigen Expressed from the Adenovirus Late Promoter", Cell, 33: 455-464 (1983) -----

-
Thurmon et al., "Hemoglobin Switching in Nonanemic Sheep. III. Evidence for Presumptive Identity between the A C Factor and Erythropoietin", Blood, 36(5): 598-606 (1970) -----

-
Udupa et al., "Erythropoiesis in the Aged Mouse", Lab. Clin. Med., 103(4), 574-580; 581-588 (1984) -----

Umemura et al., "The Mechanism of Expansion of Late Erythroid Progenitors During Erythroid Regeneration: Target Cells and Effects of Erythropoietin and Interleukin-3", Blood, 73 (7) 1993-1998 (1989) -----

Urlaub et al., "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity", Proc. Nat. Acad. Sci. (USA), vol. 77(7), 4216-

4220 (Jul. 1980) -----

Van Stone et al., "Effect of Erythropoietin on Anemia of Peritoneally Dialyzed Anephric Rats", *Kidney Intl.*, 15, 370-375 (1979) -----

Vedovato et al., "Erythropoietin Levels in Heterozygous Beta-Thalassemia", *Acta. Haematol.*, 71, 211-213 (1984) -----

Viera et al., "The pUC Plasmids, an M13mp7-derived System for Insertion Mutagenesis and Sequencing with Synthetic Universal Primers", *Gene*, 19, 259-268 (1982) -----

Wahl et al., "Effect of Chromosomal Position on Amplification of Transfected Genes in Animal Cells", *Nature*, 307: 516-520 (1984)-----

Wasley et al., "The Importance of N-and O-Linked Oligosaccharides for the Biosynthesis and In Vitro and In Vivo Biologic Activities of Erythropoietin", *Blood*, 77 (12): 2624-2632 (1991) -----

Walker et al., *Techniques in Molecular Biology*, p. 280, Macmillan Pub. Co., New York, New York (1983) -----

Wallace et al., "The Use of Synthetic Oligonucleotides as Hybridization Probes. II. Hybridization of Oligonucleotides of Mixed Sequence to Rabbit .beta.-globin DNA", *Nuc. Acids Res.*, 9(4), 879-894 (1981) -----

Wang et al., "Enhanced Production of Hepatitis B Surface Antigen in NIH 3T3 Fibroblast by Using Extrachromosomally Replicating Bovine Papillomavirus Vector", *Mol. Cell. Biol.*, 3: 1032-1039 (1983) -----

Wang et al., "Some Chemical Properties of Human Erythropoietin", *Endocrinology*, 116(6), 2286-2292 (1985) -----

Wang et al., "Renal and Extrarenal Erythropoietin Production in Male and Female Rats of Various Ages", *J. Lab. Clin. Med.*, 79(2), 181-186 (Feb. 1972) ----

Watson et al., "Structure Determination of the Intact Major Sialylated Oligosaccharide Chains of Recombinant Human Erythropoietin Expressed in Chinese Hamster Ovary Cells", *Glycobiology*, 4 (2) 227-237 (1994) -----

Weiland et al., "In Vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins", *Blut*, 44(3), 173-175 (1982) -----

Weiss et al., "Characterization of a Monoclonal Antibody to Human Erythropoietin", *P.N.A.S. (USA)*, 79, 5465-5469 (1982) -----

Weiss et al., "Studies of the Pathogenesis of Anemia of Inflammation: Mechanism of Impaired Erythropoiesis", *Am. J. Vet. Res.*, 44(10), 1832-1835 (Oct. 1983) -----

Weissman et al., "Structure and Expression of Human IFN-.alpha. Genes", *Phil. Trans. R. Soc. Lond.*, B299, 7-28 (1982) -----

White et al., "Studies on Erythropoietin", *Recent Progr. Hormone Res.*, 16:219-262 (1960) -----

Wickens et al., "Expression of a Chicken Chromosomal Ovalbumin Gene Injected into Frog Oocyte Nucleo", *Nature*, 285:628-634 (26 Jun. 1980) -----

Wide et al., "Molecular Charge Heterogeneity of Human Serum Erythropoietin", *British J. Haemat.*, 76, 121-127 (1990) -----

Wigler et al., "Transformation of Mammalian Cells with Genes from Procaryotes and Eucaryotes", *Cell*, 16: 777-785 (1979) -----

Wigler et al., "Biochemical Transfer of Single-copy Eucaryotic Genes Using Total Cellular DNA as Donor", *Cell*, 14: 725-731 (1978) -----

Wigler et al., "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", *Cell*, 11: 223-232 (1977) -----

Wigler et al., "Transformation of Mammalian Cells with an Amplifiable Dominant-Acting Gene", *Proc. Natl. Acad. Sci. (USA)*, 77: 3567-3570 (1980) -----

Wiktor et al., "Protection from Rabies by a Vaccinia Virus Recombinant Containing the Rabies Virus Glycoprotein Gene", *Proc. Natl. Acad. Sci. (USA)*, 81, 7194-7198 (1984) -----

Winnearls, "Recombinant Human Erythropoietin: 10 Years of Clinical Experience", *Nephrol. Dial. Transplant.*, 13 (2): 3-8 (1998) -----

Wojchowski et al., "Active Human Erythropoietin Expressed in Insect Cells Using a Baculovirus Vector: A Role for N-linked Oligosaccharide", *Bioch. Bioph. Acta*, 910: 224-232 (1987) -----

-

Wojchowski et al., "Site-specific Antibodies to Human Erythropoietin: Immunoaffinity Purification of Urinary and Recombinant Hormone", *Bioch. Bioph. Acta.*, 913: 10-178 (1987) -----

Woo, "A Sensitive and Rapid Method for Recombinant Phage Screening", *Methods in Enzymology*, 68, 389-395 (1979) -----

Wood et al., "Expression of Active Human Factor VIII from Recombinant DNA Clones", *Nature*, 312, 330-336 (Nov. 22, 1984) -----

Wright et al., "Regulated Expression of the Human-globin Gene Family in Murine Erythroleukaemia Cells", *Nature*, 305: 333-336 (1983) -----

Yajima et al., "Comparative Studies in Induction of Micronuclei by Three Genetically Recombinant and Urinary Human Erythropoietins", *Mutagenesis*, 8 (3): 237-241, (1993) -----

Yanagawa et al., "Hybridomas for Production of Monoclonal Antibodies to Human Erythropoietin", *Blood*, 64(2), 357-364 (Aug. 1984) -----

Yanagawa et al., "Isolation of Human Erythropoietin with Monoclonal Antibodies", *J. Biol. Chem.*, 259(5), 2707-2710 (Mar. 10, 1984) -----

Yanagi et al., "Recombinant Human Erythropoietin Produced by Namalwa Cells", *DNA*, 8(6), 419-427 (1989) -----

Yuen et al., "The Spectrum of N-linked Oligosaccharide Structures Detected by Enzymic Microsequencing on a Recombinant Soluble CD4 Glycoprotein from Chinese Hamster Ovary Cells", *Eur. J. Biochem.*, 192, 523-528 (1990) -----

Zain et al., "Nucleotide Sequence Analysis of the Leader Segments in a Cloned Copy of Adenovirus 2 Fiber mRNA", *Cell*, 16: 851-861 (1979) -----

-

Zieg et al., "Properties of Single-step Mutants of Syrian Hamster Cell Lines

Resistant to N-(Phosphonacetyl)-L-Aspartate", Mol. Cell. Biol., 3(11): 2089-2098
(1983) -----

Zinn et al., "Regulated Expression of an Extrachromosomal Human .beta.-
interferon Gene in Mouse Cells", P.N.A.S. (USA), 79, 4897-4901 (Aug. 1982) -----

ASOCIACIÓN BANCO ARGENTINO DE CÉLULAS -Argentine Cell Bank
Association-.-----

Legal Entity N°: 1,530,806-----

Upon the signed request of Dr. Aída Sterin Prync (on behalf of Laboratorios Bio
Sidus S.A.), it is hereby certified that, the biological material, whose names and
codes are detailed below, is stored in liquid nitrogen at the Cell Cultures
laboratories of the Instituto Nacional de Enfermedades Virales Humanas --
National Institute of Human Viral Diseases- (Monteagudo 2510-2700 Pergamino,
Argentina), under the custody of the Asociación Banco Argentino de Células -
Argentine Cell Bank Association- (ABAC), from February 2, 1999.:-----

NAME-----CODE-----

pVEX PLASMID-----ABAC-P-001-----

PDHFR PLASMID-----ABAC-P-002-----

46M-----ABAC-L-200-----

Buenos Aires, February 2, 1999-----

There appears a signature.-----

Dr. Ana M. Ambrosio-----

-

There appears a seal that reads Asociación Banco Argentino de Células --
Argentine Cell Bank Association-.-----

TECHNICAL DATASHEET----- (10) -----

PUBLICATION No.: AR-----

(21) APPLICATION No.:-----

On the left, there appears the Argentinian Coat of Arms -----

(19) -----

51) INT. CL:-----

I.N.P.I.-----

Argentine Republic-----

12) X INVENTION PATENT-----

UTILITY MODEL-----

(22) FILING DATE: -----

(30) PRIORITY DATA:-----

(41) APPLICATION PUBLICATION DATE: -----

-

BULLETIN No.:-----

(61) ADDITIONAL TO: -----

(62) DIVISIONAL FROM:-----

(71) APPLICANT: BIO SIDUS S.A.-----

Constitución 4234. Buenos Aires Argentina-----

(72) Inventor(s):-----

(74) Agent. License 611/900 -----

(83) Microorganisms deposit: Deposited in –ABAC- Asociación Banco Argentino de Células- Argentine Cell Bank Association – Access Code: ABAC-P002-----

(54) TITLE OF THE INVENTION: "Recombinant Human Erythropoietin Producing Cell Line and the Recombinant Human Erythropoietin produced by this cell."-----

(57) ABSTRACT: -----

The encoding gene for recombinant erythropoietin (EPO) was obtained from human genomic DNA. The gene used does not include fragments of 5' and 3' neighboring regions of the EPO gene that do not encode for the protein. The gene was cloned in a expression plasmid for eukaryotic cells which has the early promoter of SV40 virus and its polyadenylation signal, as unique elements of

expression control. The recombinant cells resulting from the transfection with the genetic constructions used, unexpectedly produced more than 50 mg of recombinant EPO per liter of culture media per day.-----

AR-----

Most representative diagram No.-----

There appears the Argentinian Coat of Arms-----

MINISTRY OF ECONOMY AND PUBLIC SERVICES-----

NATIONAL INSTITUTE OF INDUSTRIAL PROPERTY-----

INVENTION PATENT-----

February 23, 1999-----

Reception Desk-----

National Institute of Industrial Property-----

INVENTION PATENT.-----

Application of: Invention Patent-----File:-----

Under Proceeding P990100679, an INVENTION PATENT application has been filed-----

Date: 02/23/1999-----Time: 00:00-----

Resp: Coll Areco, Carlos Miguel-----P19990100679-----

File Bar Code-----Query Priority Order-----

01999010067923020000-----P19990100679-----

Argentine Republic. There appears the Argentinian Coat of Arms. I.N.P.I.-----

-

APPLICATION OF-----

-

INVENTION PATENT: X-----

MODEL OF UTILITY CERTIFICATE-----

FILING DATE: P679-02-23-99-----

There appears a seal that reads: Dr. Eduardo Arias. Legal Countersigner. Patent
National Administration-----

Applicant -----

1) Name and Surname / Company's Name:-----

BIO SIDUS S.A.-----

2) Identity Document:-----

Marital Status: -----

Marriage: -----

Spouse's Name: -----

3) Retirement Account or Pension Funds Management (AFJP): CUIT-----

No of CUIL (Unique Labor Identification Code) or CUIT (Unique Tax Identification
Code): 30-59811709-4. ----- V.A.T: Liable for V.A:T Registration.- -----

4) Registered in the National Industrial Registry (Decree-Law 19,971/72) No.- -----

5) Real Address: Constitución 4234. Buenos Aires. Argentina.-----Legal
Address: Alsina 971 – 1º Piso, of.10, Buenos Aires .-----

II. PURPOSE. -----

6) Title of invention: Recombinant Human Erythropoietin producing cell line and
the recombinant human erythropoietin produced by this cell-----

7) Type of patent: -----

a) Final: for a 20-year period-----

b) Additional to Patent No.: -----

8) Act 17,011. Priority Date: -----

Country: -----

No. -----

III. Attached Documents -----

9) Enclosures: -----

-

a) Fee receipt for the requested service -----

- b) Annexed Form in duplicate -----
- c) Cover in duplicate -----
- d) Descriptive Memory in duplicate -----
- e) Signed claims in duplicate -----
- f) 2 copies of the first claim -----
- g) Diagrams in triplicate -----
- h) Number of boards -----
- i) Reduced-scale copies-----
- j) Certified copy (Act 17,011)-----
- k) Assignment Document -----
- l) Draft drawings-----

IV Legal Entities -----

10) The corporation, represented by HUMBERTO MARIO DE PASQUALE-----
who states under oath that he is the attorney having his powers in force and that
the corporation is registered on Date: 10/07/1983 No. 7258. Page: --Book:--
Volume: A-----

V. Power of Attorney-----

11) Power of Attorney registered in -----
Registered in the INPI (National Institute of Industrial Property) under No.: Other
Registry: ----No. -----

12) In this case, authorization is given to: CARLOS MIGUEL COLL ARECO
and/or HUGO EDUARDO MARTINEZ LAHITOU-----
to proceed in this matter until its finalization with faculties to sign documents,
wave, if necessary, and request certificates.-----

13) Power of Attorney is attached-----

14) Retirement Account or / Pension Funds Management (AFJP) CONSOLIDAR
CUIL or CUIT No.: CUIT 20-04991729-6 CUIT: 20-16821007-9-----
Agent No. 611/900 -----

VI Statement -----

16) By virtue of Decree with no number dated June 7, 1901 (on Patentability in foreign countries) it is declared that the invention has not been patented abroad.-

VII. Remarks: It is stated that the legalized copies of the corresponding Power of Attorney, Minutes of Incorporation, Minutes of General Meetings and of Board of Directors are attached to the invention patent application No. P980105609-----

There appears a signature. Carlos Miguel Coll Areco (Signature of the authorized person). -----

There appears a signature. Humberto Mario De Pasquale. Attorney. (Applicant's Signature). -----

I, VIVIANA BEATRIZ CUMBO, A SWORN PUBLIC TRANSLATOR, DO HEREBY CERTIFY THE FOREGOING TO BE A TRUE TRANSLATION INTO ENGLISH OF THE PHOTOCOPY OF THE ORIGINAL DOCUMENT IN SPANISH LANGUAGE, ATTACHED HERETO, WHICH I HAVE HAD BEFORE ME. DONE AND SIGNED IN BUENOS AIRES, ON THIS FOURTEENTH DAY OF NOVEMBER, TWO THOUSAND AND THREE.-----

YO, VIVIANA BEATRIZ CUMBO, TRADUCTORA PÚBLICA MATRICULADA, CERTIFICO POR LA PRESENTE, QUE ÉSTA ES TRADUCCIÓN FIEL AL IDIOMA INGLÉS DE LA FOTOCOPIA DEL DOCUMENTO ORIGINAL REDACTADO EN IDIOMA CASTELLANO, ADJUNTA A LA PRESENTE, QUE HE TENIDO A LA VISTA, Y A LA CUAL ME REMITO, EN BUENOS AIRES, A LOS CATORCE DÍAS DEL MES DE NOVIEMBRE DE DOS MIL TRES.-----